Case number 1:18-cv-01043
Novartis Pharmaceuticals Corporation v. Accord Healthcare Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 30, 2023 | 861 | NOTICE requesting Clerk to remove Shyam Shanker as co-counsel.. (Joyce, Alexandra) (Entered: 06/30/2023) (1) |
| Jun 29, 2023 | 860 | Clerk's Taxation of Costs. Defendant's Bill of Costs 849 is DENIED. (rlr) (Entered: 06/29/2023) (5) |
| Apr 18, 2023 | 859 | Letter to The Honorable Kent A. Jordan from Daniel M. Silver, Esq. regarding Response - re 858 Letter. (Attachments: # 1 Exhibit 1)(Silver, Daniel) (Entered: 04/18/2023) (Main Document) (1) |
| Apr 18, 2023 | 859 | Letter to The Honorable Kent A. Jordan from Daniel M. Silver, Esq. regarding Response - re 858 Letter. (Attachments: # 1 Exhibit 1)(Silver, Daniel) (Entered: 04/18/2023) (Exhibit 1) (9) |
| Apr 17, 2023 | 858 | Letter to The Honorable Kent A. Jordan from Stamatios Stamoulis regarding Requesting Status Conference - re 842 USCA Mandate. (Attachments: # 1 Exhibit 1)(Stamoulis, Stamatios) (Entered: 04/17/2023) (Main Document) (1) |
| Apr 17, 2023 | 858 | Letter to The Honorable Kent A. Jordan from Stamatios Stamoulis regarding Requesting Status Conference - re 842 USCA Mandate. (Attachments: # 1 Exhibit 1)(Stamoulis, Stamatios) (Entered: 04/17/2023) (Exhibit 1) (9) |
| Nov 22, 2022 | 857 | Letter to Clerk of Court John A. Cerino from Daniel M. Slver, Esq. regarding HEC's Reply on Bill of Costs - re 856 Reply Brief. (Silver, Daniel) (Entered: 11/22/2022) (1) |
| Nov 21, 2022 | 854 | REDACTED VERSION of 852 Declaration by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 11/21/2022) (6) |
| Nov 21, 2022 | 855 | ORDER, A Teleconference has been scheduled for November 30, 2022 at 2:00 p.m. Counsel for Plaintiff shall initiate the teleconference call. If there are out-of-state counsel working on this case, local counsel are reminded of their obligation to inform their out-of-state co-counsel of this Order.( A Telephone Conference is set for 11/30/2022 at 02:00 PM before Judge Kent A. Jordan). Signed by Judge Kent A. Jordan on 11/21/2022. (apk) (Entered: 11/21/2022) (1) |
| Nov 21, 2022 | 856 | REPLY BRIEF in Further Support of HEC's Motion for Approval of Bill of Costs (D.I. 849) filed by HEC Pharm Co., Ltd., HEC Pharm Group, HEC Pharm USA Inc.. (Stamoulis, Stamatios) (Entered: 11/21/2022) (10) |
| Nov 18, 2022 | 853 | Joint Letter to the Honorable Kent A. Jordan from Stamatios Stamoulis regarding Requesting Status Conference Regarding Bond Collection Issue. (Stamoulis, Stamatios) (Entered: 11/18/2022) (3) |
| Nov 14, 2022 | 851 | OBJECTIONS by Novartis Pharmaceuticals Corporation to 849 Bill of Costs . (Silver, Daniel) (Entered: 11/14/2022) (12) |
| Nov 14, 2022 | 852 | [SEALED] DECLARATION re 851 Objections of Robert W. Trenchard by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A, # 2 Certificate of Service)(Silver, Daniel) (Entered: 11/14/2022) (0) |
| Oct 31, 2022 | 849 | BILL OF COSTS by HEC Pharm Co., Ltd., HEC Pharm Group, HEC Pharm USA Inc.. (Stamoulis, Stamatios) (Entered: 10/31/2022) (15) |
| Oct 31, 2022 | 850 | DECLARATION re 849 Bill of Costs of Mieke Malmberg by HEC Pharm Co., Ltd., HEC Pharm Group, HEC Pharm USA Inc.. (Attachments: # 1 Exhibit A-D)(Stamoulis, Stamatios) (Entered: 10/31/2022) (Main Document) (2) |
| Oct 31, 2022 | 850 | DECLARATION re 849 Bill of Costs of Mieke Malmberg by HEC Pharm Co., Ltd., HEC Pharm Group, HEC Pharm USA Inc.. (Attachments: # 1 Exhibit A-D)(Stamoulis, Stamatios) (Entered: 10/31/2022) (Exhibit A-D) (30) |
| Oct 20, 2022 | 847 | STIPULATION and [Proposed] Order to Withdraw Novartis Pharmaceuticals Corporation's Motion for a Preliminary Injunction and Tempporary Restraining Order Bond by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 10/20/2022) (3) |
| Oct 20, 2022 | 848 | SO ORDERED, re 847 Stipulation filed by Novartis Pharmaceuticals Corporation. Signed by Judge Kent A. Jordan on 10/20/2022. (apk) (Entered: 10/20/2022) (0) |
| Oct 18, 2022 | 843 | SO ORDERED, re ( 35 in 1:19-cv-01118-LPS, 841 in 1:18-cv-01043-KAJ) STIPULATION TO EXTEND TIME to file public, redacted versions of Mylan's Opposition to Novartis's Emergency Motion for a Temporary Restraining Order and the declarations filed in support of same filed by Novartis Pharmaceuticals Corporation. Signed by Judge Kent A. Jordan on 10/18/2022. (apk) (Entered: 10/18/2022) (0) |
| Oct 18, 2022 | 844 | REDACTED VERSION of 825 Answering Brief in Opposition, to Novartis's Emergency Motion for a Temporary Restraining Order by Mylan Pharmaceuticals, Inc.. (Cottrell, Frederick) (Entered: 10/18/2022) (26) |
| Oct 18, 2022 | 845 | REDACTED VERSION of 826 Declaration of Shannon M. Bloodworth by Mylan Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-G)(Cottrell, Frederick) (Entered: 10/18/2022) (Main Document) (4) |
| Oct 18, 2022 | 846 | REDACTED VERSION of 827 Declaration of Keith Meckstroth by Mylan Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A)(Cottrell, Frederick) (Entered: 10/18/2022) (Main Document) (6) |
| Oct 18, 2022 | 845 | REDACTED VERSION of 826 Declaration of Shannon M. Bloodworth by Mylan Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-G)(Cottrell, Frederick) (Entered: 10/18/2022) (Exhibit A-G) (30) |
| Oct 18, 2022 | 846 | REDACTED VERSION of 827 Declaration of Keith Meckstroth by Mylan Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A)(Cottrell, Frederick) (Entered: 10/18/2022) (Exhibit A) (2) |
| Oct 17, 2022 | 841 | STIPULATION TO EXTEND TIME to file public, redacted versions of Mylan's Opposition to Novartis's Emergency Motion for a Temporary Restraining Order and the declarations filed in support of same (C.A. No. 18-1043, D.I. Nos. 82527; C.A. No. 19-1118, D.I. Nos. 1921) to October 18, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 10/17/2022) (2) |
| Oct 17, 2022 | 842 | MANDATE of USCA as to D.I. 786 Notice of Appeal (Federal Circuit) filed by HEC Pharm USA Inc., HEC Pharm Co., Ltd.. USCA Decision: Reversed. (Attachments: # 1 Opinion, # 2 Judgment)(mpb) (Entered: 10/18/2022) (Main Document) (2) |
| Oct 17, 2022 | 842 | MANDATE of USCA as to D.I. 786 Notice of Appeal (Federal Circuit) filed by HEC Pharm USA Inc., HEC Pharm Co., Ltd.. USCA Decision: Reversed. (Attachments: # 1 Opinion, # 2 Judgment)(mpb) (Entered: 10/18/2022) (Opinion) (22) |
| Oct 17, 2022 | 842 | MANDATE of USCA as to D.I. 786 Notice of Appeal (Federal Circuit) filed by HEC Pharm USA Inc., HEC Pharm Co., Ltd.. USCA Decision: Reversed. (Attachments: # 1 Opinion, # 2 Judgment)(mpb) (Entered: 10/18/2022) (Judgment) (2) |
| Oct 13, 2022 | 833 | MOTION for Pro Hac Vice Appearance of Attorney Aileen C. Huang and Darish Huynh - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 10/13/2022) (4) |
| Oct 13, 2022 | 834 | SO ORDERED, re 833 MOTION for Pro Hac Vice Appearance of Attorney Aileen C. Huang and Darish Huynh filed by Novartis Pharmaceuticals Corporation. Signed by Judge Kent A. Jordan on 10/13/2022. (apk) (Entered: 10/13/2022) (0) |
| Oct 13, 2022 | 835 | REDACTED VERSION of (820 in 1:18-cv-01043-KAJ, 820 in 1:18-cv-01043-KAJ, 14 in 1:19-cv-01118-LPS, 14 in 1:19-cv-01118-LPS) Emergency MOTION for Temporary Restraining Order and MOTION for Preliminary Injunction by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 10/13/2022) (6) |
| Oct 13, 2022 | 836 | REDACTED VERSION of (15 in 1:19-cv-01118-LPS) Opening Brief in Support, (821 in 1:18-cv-01043-KAJ) Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 10/13/2022) (20) |
| Oct 13, 2022 | 837 | REDACTED VERSION of (822 in 1:18-cv-01043-KAJ, 16 in 1:19-cv-01118-LPS) Declaration, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 10/13/2022) (30) |
| Oct 13, 2022 | 838 | REDACTED VERSION of (823 in 1:18-cv-01043-KAJ, 17 in 1:19-cv-01118-LPS) Declaration, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 10/13/2022) (30) |
| Oct 13, 2022 | 839 | Letter to Honorable Kent A. Jordan from Frederick L. Cottrell, III regarding Denial of motion to stay issuance of mandate. (Attachments: # 1 Exhibit A)(Cottrell, Frederick) (Entered: 10/13/2022) (Main Document) (1) |
| Oct 13, 2022 | 840 | STIPULATION TO EXTEND TIME to file public, redacted versions of Mylans Opposition to Novartiss Emergency Motion for a Temporary Restraining Order and the declarations filed in support of same to October 17, 2022 - filed by Mylan Pharmaceuticals, Inc.. (Rawnsley, Jason) (Entered: 10/13/2022) (2) |
| Oct 13, 2022 | 839 | Letter to Honorable Kent A. Jordan from Frederick L. Cottrell, III regarding Denial of motion to stay issuance of mandate. (Attachments: # 1 Exhibit A)(Cottrell, Frederick) (Entered: 10/13/2022) (Exhibit A) (3) |
| Oct 12, 2022 | 830 | Official Transcript of Motion held on 10.11.2022 before Judge Kent Jordan. Court Reporter/Transcriber Michele Rolfe,Email: michele_rolfe@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 11/2/2022. Redacted Transcript Deadline set for 11/14/2022. Release of Transcript Restriction set for 1/10/2023. (Rolfe, Michele) (Entered: 10/12/2022) (40) |
| Oct 12, 2022 | 831 | STATEMENT re (829 in 1:18-cv-01043-KAJ, 829 in 1:18-cv-01043-KAJ, 25 in 1:19-cv-01118-LPS, 25 in 1:19-cv-01118-LPS) Temporary Restraining Order,, Set Deadlines/Hearings, Unsecured Bond for Temporary Restraining Order by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 10/12/2022) (2) |
| Oct 12, 2022 | 832 | STIPULATION TO EXTEND TIME to file public redacted versions of Novartis's Motion for a Temporary Restraining Order and supporting papers (D.I. Nos. 820-823, C.A. No. 18-1043 / D.I. Nos. 14-17, C.A. 19-1118) to October 13, 2022 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 10/12/2022) (2) |
| Oct 11, 2022 | 828 | PROPOSED ORDER Temporary Restraining Order and Setting Hearing on Motion for Preliminary Injunction by Novartis Pharmaceuticals Corporation. (Silver, Daniel) (Entered: 10/11/2022) (4) |
| Oct 11, 2022 | 829 | TEMPORARY RESTRAINING ORDER, Plaintiff's Motion for a Temporary Restraining Order is GRANTED. A hearing is set for November 17th, 2022, at 10:00 a.m. to consider Plaintiff's Motion for Preliminary Injunction. (SEE ORDER FOR FURTHER DETAILS) ( A Motion Hearing is set for 11/17/2022 at 10:00 AM in To Be Determined before Judge Kent A. Jordan). Signed by Judge Kent A. Jordan on 10/11/2022. (apk) (Entered: 10/11/2022) (4) |
| Oct 7, 2022 | 824 | Letter to The Honorable Kent A. Jordan from Daniel M. Silver, Esq. regarding Request to Seal the Courtroom. (Silver, Daniel) (Entered: 10/07/2022) (1) |
| Oct 7, 2022 | 825 | [SEALED] ANSWERING BRIEF in Opposition re 820 Emergency MOTION for Temporary Restraining Order and MOTION for Preliminary Injunction filed by Mylan Pharmaceuticals, Inc..Reply Brief due date per Local Rules is 10/14/2022. (Cottrell, Frederick) (Entered: 10/07/2022) (0) |
| Oct 7, 2022 | 826 | [SEALED] DECLARATION re 825 Answering Brief in Opposition, by Mylan Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A-G)(Cottrell, Frederick) (Entered: 10/07/2022) (0) |
| Oct 7, 2022 | 827 | [SEALED] DECLARATION re 825 Answering Brief in Opposition, by Mylan Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A)(Cottrell, Frederick) (Entered: 10/07/2022) (0) |
| Oct 5, 2022 | 820 | [SEALED] Emergency MOTION for Temporary Restraining Order and, MOTION for Preliminary Injunction - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Text of Proposed Order, # 2 Certificate of Service)(Silver, Daniel) (Entered: 10/05/2022) (0) |
| Oct 5, 2022 | 821 | [SEALED] OPENING BRIEF in Support re 820 Emergency MOTION for Temporary Restraining Order and MOTION for Preliminary Injunction filed by Novartis Pharmaceuticals Corporation.Answering Brief/Response due date per Local Rules is 10/19/2022. (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 10/05/2022) (0) |
| Oct 5, 2022 | 822 | [SEALED] DECLARATION re (14 in 1:19-cv-01118-LPS, 14 in 1:19-cv-01118-LPS, 820 in 1:18-cv-01043-KAJ, 820 in 1:18-cv-01043-KAJ) Emergency MOTION for Temporary Restraining Order and MOTION for Preliminary Injunction of Robert W. Trenchard by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit A-K, # 2 Certificate of Service)(Silver, Daniel) (Entered: 10/05/2022) (0) |
| Oct 5, 2022 | 823 | [SEALED] DECLARATION re (14 in 1:19-cv-01118-LPS, 14 in 1:19-cv-01118-LPS, 820 in 1:18-cv-01043-KAJ, 820 in 1:18-cv-01043-KAJ) Emergency MOTION for Temporary Restraining Order and MOTION for Preliminary Injunction of Christopher Vellturo, Ph.D. by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) (Entered: 10/05/2022) (0) |
| Sep 21, 2022 | 819 | ORDER of USCA as to 786 Notice of Appeal (Federal Circuit) filed by HEC Pharm USA Inc., HEC Pharm Co., Ltd.. Decision of USCA: The petition for panel rehearing is denied. The petition for rehearing en banc is denied. The mandate of the court will issue September 27, 2022. (nmg) (Entered: 09/21/2022) (3) |
| Apr 11, 2022 | N/A | Case No Longer Referred to Mediation (0) Docket Text: CASE NO LONGER REFERRED to Magistrate Judge Burke for the purpose of exploring ADR. Please see the Court's Standing Order No. 2022-2 dated March 14, 2022. (dlb) |
| Apr 1, 2022 | 818 | Letter (2) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Joint Status Report - re (38 in 1:18-cv-01040-LPS) Order, (55 in 1:18-cv-01038-LPS) Order,. (Silver, Daniel) |
| Jan 21, 2021 | 817 | Judgment (3) Docket Text: FINAL JUDGMENT AND ORDER OF INJUNCTION - re Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc. Signed by Judge Kent A. Jordan on 1/21/21. (amf) |
| Jan 19, 2021 | 816 | Proposed Consent Judgment (3) Docket Text: PROPOSED CONSENT JUDGMENT and Order of Injunction by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Dec 16, 2020 | 815 | Order (1) Docket Text: ORDER - In accordance with the Court's December 10, 2020 Order (D.I. [810]), the Clerk's Office is hereby directed to unseal the Memorandum Opinion of December 10, 2020 (D.I. [809]). Signed by Judge Kent A. Jordan on 12/16/2020. (amf) |
| Dec 15, 2020 | 812 | Memorandum Opinion (7) Docket Text: MEMORANDUM OPINION. Signed by Judge Kent A. Jordan on 12/15/2020. (amf) |
| Dec 15, 2020 | 813 | Order on Motion for Miscellaneous Relief (1) Docket Text: ORDER - Plaintiff Novartis's Motion to Extinguish Any Claim by Defendant HEC To The Preliminary Injunction Bond (D.I. [785]) is GRANTED. Signed by Judge Kent A. Jordan on 12/15/2020. (amf) |
| Dec 15, 2020 | 814 | Letter (1) Docket Text: Letter to The Honorable Kent A. Jordan from Daniel M. Silver, Esq. regarding Parties' Request to Unseal Memorandum Opinion (D.I. 809) - re [810] Order,. (Silver, Daniel) |
| Dec 10, 2020 | 809 | Memorandum Opinion (9) Docket Text: MEMORANDUM OPINION. Signed by Judge Kent A. Jordan on 12/10/2020.This order has been emailed to local counsel. (myr) |
| Dec 10, 2020 | 810 | Order (1) Docket Text: ORDER, re D.I. [809] Memorandum Opinion (UNDER SEAL). Counsel shall provide the Court with proposed redactions to that document on or before the close of business on December 21, 2020. After that time the Court will unseal the Memorandum Opinion, setting forth the rulings, with any redactions deemed appropriate by the Court. Signed by Judge Kent A. Jordan on 12/10/2020. (myr) |
| Dec 10, 2020 | 811 | Order on Motion to Stay (1) Docket Text: ORDER, denying D.I.[784] Motion for partial Stay of the final judgment; denying as moot D.I.[796] Motion for Leave to File. Signed by Judge Kent A. Jordan on 12/10/2020. (myr) |
| Dec 2, 2020 | 808 | Judgment (3) Docket Text: FINAL JUDGMENT and ORDER OF INJUNCTION re [807] Proposed Order filed by Novartis Pharmaceuticals Corporation. Signed by Judge Kent A. Jordan on 12/2/2020. (myr) |
| Nov 30, 2020 | 807 | Proposed Order (3) Docket Text: PROPOSED ORDER Final Judgment and Order of Injunction by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Nov 12, 2020 | 806 | Judgment (3) Docket Text: FINAL JUDGMENT and ORDER OF INJUNCTION. Signed by Judge Kent A. Jordan on 11/12/2020. (nmg) |
| Nov 11, 2020 | 805 | Proposed Order (3) Docket Text: PROPOSED ORDER Final Judgment and Order of Injunction as to Defendants Torrent Pharmaceuticals, Ltd. and Torrent Pharma, Inc. by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Oct 27, 2020 | 804 | Consent Judgment (3) Docket Text: FINAL JUDGMENT AND ORDER OF INJUNCTION. Signed by Judge Kent A. Jordan on 10/27/2020. (nmg) |
| Oct 26, 2020 | 803 | Proposed Consent Judgment (3) Docket Text: PROPOSED CONSENT JUDGMENT and Order of Injunction by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Oct 22, 2020 | 802 | Reply Brief (2) Docket Text: REPLY BRIEF re [796] MOTION for Leave to File a Sur-Reply In Support of Its Opposition to HEC's Motion for Partial Stay of the Final Judgment filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Oct 21, 2020 | 798 | Notice Requesting Removal of Co-Counsel (2) Docket Text: NOTICE requesting Clerk to remove Michael P. Kelly as co-counsel.. (Silver, Daniel) |
| Oct 21, 2020 | 799 | Judgment (4) Docket Text: FINAL JUDGMENT AND ORDER OF INJUNCTION- in favor of Novartis Pharmaceuticals Corporation against Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd. re [793] Proposed Consent Judgment filed by Novartis Pharmaceuticals Corporation. Signed by Judge Kent A. Jordan on 10/21/2020. (myr) |
| Oct 21, 2020 | 800 | Judgment (3) Docket Text: FINAL JUDGMENT AND ORDER OF INJUNCTION- in favor of Novartis Pharmaceuticals Corporation against Sun Pharma Global FZE, Sun Pharmaceutical Industries Inc., Sun Pharmaceutical Industries Ltd., re [795] Proposed Consent Judgment filed by Novartis Pharmaceuticals Corporation. Signed by Judge Kent A. Jordan on 10/21/2020. (myr) |
| Oct 21, 2020 | 801 | Answering Brief in Opposition (4) Docket Text: ANSWERING BRIEF in Opposition re [796] MOTION for Leave to File a Sur-Reply In Support of Its Opposition to HEC's Motion for Partial Stay of the Final Judgment filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..Reply Brief due date per Local Rules is 10/28/2020. (Stamoulis, Stamatios) |
| Oct 20, 2020 | 797 | USCA Notice of Docketing ROA (4) Docket Text: NOTICE of Docketing Record on Appeal from USCA for the Federal Circuit re [786] Notice of Appeal (Federal Circuit) filed by HEC Pharm USA Inc. and HEC Pharm Co., Ltd. USCA Case Number 21-1070. (nmg) |
| Oct 19, 2020 | 795 | Proposed Consent Judgment (3) Docket Text: PROPOSED CONSENT JUDGMENT and Order of Injunction as to Defendants Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Inc., and Sun Pharma Global FZE by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Oct 19, 2020 | 796 | Main Document (3) Docket Text: MOTION for Leave to File a Sur-Reply In Support of Its Opposition to HEC's Motion for Partial Stay of the Final Judgment - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Text of Proposed Order)(Silver, Daniel) |
| Oct 19, 2020 | 796 | Exhibit A (3) |
| Oct 19, 2020 | 796 | Exhibit B (6) |
| Oct 19, 2020 | 796 | Text of Proposed Order (1) |
| Oct 16, 2020 | 792 | Reply Brief (10) Docket Text: REPLY BRIEF re [784] MOTION to Stay re [783] Judgment filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc.. (Stamoulis, Stamatios) |
| Oct 16, 2020 | 793 | Proposed Consent Judgment (4) Docket Text: PROPOSED CONSENT JUDGMENT and Order of Injunction as to Defendants Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Oct 16, 2020 | 794 | Reply Brief (7) Docket Text: REPLY BRIEF re [785] MOTION to Extinguish Any Claim by Defendant HEC To The Preliminary Injunction Bond filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Oct 15, 2020 | 790 | Redacted Document (18) Docket Text: REDACTED VERSION of [788] Answering Brief in Opposition, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Oct 15, 2020 | 791 | Redacted Document (30) Docket Text: REDACTED VERSION of [789] Declaration by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Oct 9, 2020 | N/A | APPEAL - Credit Card Payment (0) Docket Text: APPEAL - Credit Card Payment of $505.00 received re [786] Notice of Appeal (Federal Circuit) filed by HEC Pharm USA Inc., HEC Pharm Co., Ltd.. ( Filing fee $505, receipt number ADEDC-3255251.) (Stamoulis, Stamatios) |
| Oct 9, 2020 | N/A | Description not available (0) Docket Text: Notification regarding [786] Notice of Appeal (Federal Circuit) sent to Reporter Gaffigan (nmg) |
| Oct 9, 2020 | N/A | Notice of Appeal and Docket Sheet to USCA (0) Docket Text: Notice of Appeal and Docket Sheet to US Court of Appeals for the Federal Circuit re [786] Notice of Appeal (Federal Circuit). (nmg) |
| Oct 9, 2020 | 786 | Notice of Appeal (Federal Circuit) (2) Docket Text: NOTICE OF APPEAL to the Federal Circuit of [770] Order, [780] Judgment,,, Order,, . Appeal filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc.. (Stamoulis, Stamatios) |
| Oct 9, 2020 | 787 | Answering Brief in Opposition (14) Docket Text: ANSWERING BRIEF in Opposition re [785] MOTION to Extinguish Any Claim by Defendant HEC To The Preliminary Injunction Bond filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..Reply Brief due date per Local Rules is 10/16/2020. (Stamoulis, Stamatios) |
| Sep 25, 2020 | 784 | Motion to Stay (16) Docket Text: MOTION to Stay re [783] Judgment - filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc.. (Stamoulis, Stamatios) |
| Sep 25, 2020 | 785 | Main Document (8) Docket Text: MOTION to Extinguish Any Claim by Defendant HEC To The Preliminary Injunction Bond - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-B, # (2) Text of Proposed Order)(Silver, Daniel) |
| Sep 25, 2020 | 785 | Exhibit A-B (14) |
| Sep 25, 2020 | 785 | Text of Proposed Order (1) |
| Sep 23, 2020 | 782 | Proposed Order (3) Docket Text: PROPOSED ORDER Proposed Final Judgment and Order of Injunction against DefendantAlkem Laboratories, Ltd. by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Sep 23, 2020 | 783 | Judgment (3) Docket Text: FINAL JUDGMENT AND ORDER OF INJUNCTION - in favor of Novartis Pharmaceuticals Corporation against Alkem Laboratories Ltd. Signed by Judge Kent A. Jordan on 9/23/2020. (amf) |
| Sep 18, 2020 | 781 | Notice Requesting Removal of Co-Counsel (1) Docket Text: NOTICE requesting Clerk to remove Jaimin H. Shah as co-counsel.. (Dorsney, Kenneth) |
| Sep 11, 2020 | 780 | Judgment (5) Docket Text: ORDER, FINAL JUDGMENT, AND INJUNCTION - Final judgment is entered in favor of Novartis and against HEC (1) on Novartis' claims of induced and contributory infringement under 35 U.S.C. ยง 271(e)(2) of claims 1-6 of the '405 patent by HEC's ANDA No. 207939 and (2) on HEC's defenses and counterclaims of non-infringement and invalidity of claims 1-6 of the '405 patent, and HEC's counterclaims are dismissed with prejudice. SO ORDERED by Judge Kent A. Jordan on 9/11/2020. (*See attached Order for further details.) (amf) |
| Aug 28, 2020 | 778 | Proposed Order (5) Docket Text: PROPOSED ORDER Final Judgment, and Injunction by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Aug 28, 2020 | 779 | Letter (1) Docket Text: Letter to The Honorable Kent A. Jordan, Circuit Judge from Daniel M. Silver regarding Outstanding Dispute - re [778] Proposed Order. (Silver, Daniel) |
| Aug 25, 2020 | N/A | SO ORDERED (0) Docket Text: SO ORDERED re [776] STIPULATION TO EXTEND TIME The Deadline for the parties to submit a form of Judgment to August 28, 2020 filed by Novartis Pharmaceuticals Corporation. Entered by Judge Kent A. Jordan on 8/25/2020. (kmd) |
| Aug 24, 2020 | 776 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME The Deadline for the parties to submit a form of Judgment to August 28, 2020 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Aug 21, 2020 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorneys Shyam Shanker and Sung Bin Lee for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (kmd) |
| Aug 20, 2020 | 774 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME the Deadline for the Parties to Submit a Form of Judgment to August 24, 2020 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Aug 17, 2020 | 773 | Order (1) Docket Text: ORDER - directing Clerk's Office to Unseal re [769] Findings of Fact & Conclusions of Law. Signed by Judge Kent A. Jordan on 8/17/20. (rwc) |
| Aug 12, 2020 | 772 | Letter (1) Docket Text: Letter to The Honorable Kent A. Jordan from Daniel M. Silver regarding Redactions - re [769] Findings of Fact & Conclusions of Law. (Joyce, Alexandra) |
| Aug 10, 2020 | 769 | Findings of Fact & Conclusions of Law (37) Docket Text: FINDINGS OF FACT AND CONCLUSIONS OF LAW. Signed by Judge Kent A. Jordan on 8/10/2020. This order has been emailed to local counsel. (UNSEALED PURSUANT TO ORDER DI 773) (nmg) Modified on 8/17/2020 (rwc). |
| Aug 10, 2020 | 770 | Order (1) Docket Text: ORDER, Whereas the Court's August 10, 2020 Post-Trial Findings of Fact and Conclusions of Law has been sealed, counsel shall provide the Court with proposed redactions to that document on or before the close of business on August 21, 2020. After that time the Court will unseal the Post-Trial Findings of Fact and Conclusions of Law, setting forth the rulings, with any redactions deemed appropriate by the Court. Signed by Judge Kent A. Jordan on 8/10/2020. (nmg) |
| Aug 10, 2020 | 771 | Order (1) Docket Text: ORDER, For the reasons set forth in the Post-Trial Findings of Act and Conclusions of Law issued in this matter today, the parties shall confer and, within ten days, submit a form of judgment order giving effect to the conclusions set forth therein. Signed by Judge Kent A. Jordan on 8/10/2020. (nmg) |
| Jun 25, 2020 | 768 | Consent Judgment (4) Docket Text: CONSENT JUDGMENT AND ORDER OF INJUNCTION - re Strides Global Pharma Private Limited, Strides Pharma, Inc. Signed by Judge Kent A. Jordan on 6/25/2020. (amf) |
| Jun 24, 2020 | 767 | Proposed Consent Judgment (4) Docket Text: PROPOSED CONSENT JUDGMENT as to Defendants Strides Global Pharma Private Limited and Strides Pharma, Inc. by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jun 20, 2020 | 6 | Motion for Leave to Appear Pro Hac Vice (3) |
| May 27, 2020 | 765 | Consent Judgment (3) Docket Text: CONSENT JUDGMENT AND ORDER OF INJUNCTION - re Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals Limited. Signed by Judge Kent A. Jordan on 5/27/2020. (amf) |
| May 27, 2020 | 766 | Consent Judgment (3) Docket Text: CONSENT JUDGMENT AND ORDER OF INJUNCTION - re Emcure Pharmaceuticals and Heritage Pharmaceuticals Inc. Signed by Judge Kent A. Jordan on 5/27/2020. (amf) |
| May 26, 2020 | 764 | Proposed Consent Judgment (3) Docket Text: PROPOSED CONSENT JUDGMENT as to Defendants Emcure Pharmaceuticals Ltd. and Heritage Pharmaceuticals Inc. by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 20, 2020 | 763 | Proposed Consent Judgment (3) Docket Text: PROPOSED CONSENT JUDGMENT and Order of Injunction as to Glenmark Pharmaceuticals Limited by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 8, 2020 | 756 | Statement (30) Docket Text: STATEMENT / Novartis's Proposed Conclusions of Law Regarding Validity of U.S. Pat. No. 9,187,405 by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 8, 2020 | 757 | Proposed Findings of Fact (30) Docket Text: Proposed Findings of Fact by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 8, 2020 | 758 | POST Trial Brief (30) Docket Text: POST TRIAL BRIEF / Novartis's Post-Trial Brief on the Validity of U.S. Pat. No. 9,187,405 by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 8, 2020 | 759 | POST Trial Brief (21) Docket Text: POST TRIAL BRIEF Responsive to Non-Infringement by HEC Pharm Co., Ltd., HEC Pharm USA Inc.. (Stamoulis, Stamatios) |
| May 8, 2020 | 760 | Proposed Findings of Fact (6) Docket Text: Proposed Findings of Fact by HEC Pharm Co., Ltd., HEC Pharm USA Inc.. (Stamoulis, Stamatios) |
| May 8, 2020 | 761 | Notice (Other) (10) Docket Text: NOTICE of Supplemental Proposed Conclusions of Law by HEC Pharm Co., Ltd., HEC Pharm USA Inc. (Stamoulis, Stamatios) |
| May 4, 2020 | 755 | Consent Judgment (3) Docket Text: CONSENT JUDGMENT. Signed by Judge Kent A. Jordan on 5/4/2020. (nmg) |
| May 1, 2020 | 754 | Proposed Consent Judgment (3) Docket Text: PROPOSED CONSENT JUDGMENT and Order of Injunction as to Prinston by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Apr 30, 2020 | 752 | Order (3) Docket Text: CONSENT JUDGMENT and ORDER OF INJUNCTION, Judgment is entered that the accused product (the subject of Abbreviated New Drug Application No. 210252) infringes all claims of the '405 Patent asserted against Bionpharma in this action. Pursuant to the terms of the Settlement and License Agreement, all other claims and counterclaims by Bionpharma or against Bionpharma are dismissed WITH PREJUDICE. Novartis and Bionpharma each expressly waive any right to appeal or otherwise move for relief from this Consent Judgment and Order of lnjunction. *See Order for further details. Signed by Judge Kent A. Jordan on 4/30/2020.(lak) |
| Apr 30, 2020 | 753 | Order (3) Docket Text: CONSENT JUDGMENT AND ORDER OF INJUNCTION, Judgment is entered that the accused product (the subject of Abbreviated New Drug Application No. 207945) infringes all claims of the '405 Patent asserted against Ezra in this action. Pursuant to the terms of the Settlement and License Agreement, all other claims and counterclaims by Ezra or against Ezra are dismissed WITH PREJUDICE. Novartis and Ezra each expressly waive any right to appeal or otherwise move for relief from this Consent Judgment and Order of lnjunction. *See Order for further details. Signed by Judge Kent A. Jordan on 4/30/2020. (lak) |
| Apr 29, 2020 | 750 | Proposed Consent Judgment (3) Docket Text: PROPOSED CONSENT JUDGMENT and Order of Injunction as to Bionpharma by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Apr 29, 2020 | 751 | Proposed Consent Judgment (3) Docket Text: PROPOSED CONSENT JUDGMENT and Order of Injunction as to Ezra by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Apr 23, 2020 | 749 | Main Document (3) Docket Text: NOTICE of of Supplemental Authority by HEC Pharm Co., Ltd., HEC Pharm USA Inc. (Attachments: # (1) Exhibit A)(Stamoulis, Stamatios) |
| Apr 23, 2020 | 749 | Exhibit A (8) |
| Apr 15, 2020 | 748 | Proposed Order (30) Docket Text: PROPOSED ORDER Corrected Proposed Conclusions of Law re [746] Proposed Order by HEC Pharm Co., Ltd., HEC Pharm USA Inc.. (Stamoulis, Stamatios) |
| Apr 10, 2020 | 742 | POST Trial Brief (29) Docket Text: POST TRIAL BRIEF on HEC's Infringement of U.S. Pat. No. 9,187,405 by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Apr 10, 2020 | 743 | POST Trial Brief (30) Docket Text: POST TRIAL BRIEF on Invalidity by HEC Pharm Co., Ltd., HEC Pharm Group, HEC Pharm USA Inc.. (Stamoulis, Stamatios) |
| Apr 10, 2020 | 744 | Proposed Findings of Fact (30) Docket Text: Proposed Findings of Fact by HEC Pharm Co., Ltd., HEC Pharm Group, HEC Pharm USA Inc.. (Stamoulis, Stamatios) |
| Apr 10, 2020 | 745 | Proposed Findings of Fact (9) Docket Text: Proposed Findings of Fact by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Apr 10, 2020 | 746 | Proposed Order (30) Docket Text: PROPOSED ORDER Proposed Conclusions of Law by HEC Pharm Co., Ltd., HEC Pharm USA Inc.. (Stamoulis, Stamatios) |
| Apr 10, 2020 | 747 | Statement (10) Docket Text: STATEMENT Novartis's Proposed Conclusions of Law Regarding HEC's Infringement of U.S. Pat. No. 9,187,405 by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Apr 2, 2020 | 738 | Transcript (344) Docket Text: Official Transcript of Bench Trial - Volume 1 held on March 2, 2020 before Judge Kent A. Jordan. Court Reporter Gail Inghram Verbano, email: GailTheCourtReporter@gmail.com. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/23/2020. Redacted Transcript Deadline set for 5/4/2020. Release of Transcript Restriction set for 7/1/2020. (bpg) |
| Apr 2, 2020 | 739 | Transcript (262) Docket Text: Official Transcript of Bench Trial - Volume 2 held on March 3, 2020 before Judge Kent A. Jordan. Court Reporter Gail Inghram Verbano, email: GailTheCourtReporter@gmail.com. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/23/2020. Redacted Transcript Deadline set for 5/4/2020. Release of Transcript Restriction set for 7/1/2020. (bpg) |
| Apr 2, 2020 | 740 | Transcript (337) Docket Text: Official Transcript of Bench Trial - Volume 3 held on March 4, 2020 before Judge Kent A. Jordan. Court Reporter Gail Inghram Verbano, email: GailTheCourtReporter@gmail.com. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/23/2020. Redacted Transcript Deadline set for 5/4/2020. Release of Transcript Restriction set for 7/1/2020. (bpg) |
| Apr 2, 2020 | 741 | Transcript (69) Docket Text: Official Transcript of Bench Trial - Volume 4 held on March 5, 2020 before Judge Kent A. Jordan. Court Reporter Gail Inghram Verbano, email: GailTheCourtReporter@gmail.com. Transcript may be viewed at the court public terminal or ordered/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/23/2020. Redacted Transcript Deadline set for 5/4/2020. Release of Transcript Restriction set for 7/1/2020. (bpg) |
| Mar 11, 2020 | 737 | Notice (Other) (1) Docket Text: NOTICE of Withdrawal of Appearance (Jennifer M. Rutter) by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd. (Rutter, Jennifer) |
| Mar 10, 2020 | 736 | Redacted Document (6) Docket Text: REDACTED VERSION of [734] Letter by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Phillips, John) |
| Mar 5, 2020 | N/A | Bench Trial - Completed (0) Docket Text: Minute Entry for proceedings held before Judge Kent A. Jordan - Bench Trial (day 4) completed on 3/5/2020. (Court Reporter Gail Verbano.) (amf) |
| Mar 4, 2020 | N/A | Bench Trial - Held (0) Docket Text: Minute Entry for proceedings held before Judge Kent A. Jordan - Bench Trial day 3 held on 3/4/2020. (Court Reporter Gail Verbano.) (amf) Modified on 3/5/2020 (amf). |
| Mar 3, 2020 | N/A | Bench Trial - Held (0) Docket Text: Minute Entry for proceedings held before Judge Kent A. Jordan - Bench Trial day 2 held on 3/3/2020. (Court Reporter Gail Verbano.) (lak) Modified on 3/5/2020 (amf). |
| Mar 3, 2020 | 733 | Order on Motion to Appear Pro Hac Vice (4) Docket Text: ORDER granting [730] MOTION for Pro Hac Vice Appearance of Attorney Steven W. Hartsell. Signed by Judge Kent A. Jordan on 3/2/2020. (nmg) |
| Mar 2, 2020 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: D.I. [732] Order uploaded. (lak) |
| Mar 2, 2020 | N/A | Bench Trial - Begun (0) Docket Text: Minute Entry for proceedings held before Judge Kent A. Jordan - Bench Trial day 1 held on 3/2/2020. (Court Reporter Gail Verbano.) (amf) Modified on 3/5/2020 (amf). |
| Mar 2, 2020 | 731 | Main Document (2) Docket Text: Letter to The Honorable Kent A. Jordan from Daniel M. Silver, Esq. regarding Dispute Regarding Deposition Designations for Trial. (Attachments: # (1) Exhibit A)(Silver, Daniel) |
| Mar 2, 2020 | 731 | Exhibit A (6) |
| Mar 2, 2020 | 732 | Order (4) Docket Text: ORDER re [728] Stipulation of Dismissal filed by Novartis Pharmaceuticals Corporation. All claims, counterclaims, defenses, motions and petitions asserted in this Action by Hetero or against Hetero are dismissed with prejudice. Each Party is to bear its own costs, expenses, and attorneys' fees. *See Order for further details*. Signed by Judge Kent A. Jordan on 3/2/2020. (lak) (lak). |
| Mar 1, 2020 | 730 | Motion for Leave to Appear Pro Hac Vice (4) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Steven W. Hartsell - filed by HEC Pharm Co., Ltd., HEC Pharm Group, HEC Pharm USA Inc.. (Stamoulis, Stamatios) |
| Feb 29, 2020 | 728 | Stipulation of Dismissal (4) Docket Text: STIPULATION of Dismissal Between Novartis and Hetero by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Feb 29, 2020 | 729 | Stipulation of Dismissal (4) Docket Text: STIPULATION of Dismissal Between Novartis and Zydus/Cadila by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Feb 28, 2020 | N/A | Telephone Conference (0) Docket Text: Minute Entry for proceedings held before Judge Kent A. Jordan -Teleconference 2/28/20 at 3:25 p.m. with counsel Daniel Silver and Kenneth Dorsney regarding the Stipulation and Proposed Order Staying the case as to Hetero (D.I. [727]). Judge told counsel that unless the case was settled in its entirety, counsel should be prepared to go to trial on Monday. He will not sign the stipulation for a stay. (No court reporter was available.) (lak) Modified on 2/28/2020 (amf). |
| Feb 28, 2020 | N/A | Telephone Conference (0) Docket Text: Minute Entry for proceedings held before Judge Kent A. Jordan - Further teleconference with counsel, Daniel Silver and Robert Trenchard for Novartis, and Kenneth Dorsney and Howard Suh for defendant Hetero, reiterating that the parties either settle the case in its entirety or be in court on Monday for trial. Telephone Conference held on 2/28/2020. (amf) |
| Feb 28, 2020 | 727 | Stipulation (5) Docket Text: Joint STIPULATION and [Proposed] Order Staying the Case as to Hetero by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Feb 27, 2020 | 726 | Stipulation (2) Docket Text: STIPULATION and [Proposed] Order Regarding Use of Revised Zydus Label at Trial by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Feb 25, 2020 | 725 | Main Document (9) Docket Text: EXHIBIT re [715] Proposed Pretrial Order [CORRECTED] Exhibit 6 by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Letter to the Honorable Kent A. Jordan, Circuit Judge from Daniel M. Silver)(Silver, Daniel) |
| Feb 25, 2020 | 725 | Letter to the Honorable Kent A. Jordan, Circuit Judge from Daniel M. Silver (1) |
| Feb 21, 2020 | N/A | Pretrial Conference - Initial (0) Docket Text: Minute Entry for proceedings held before Judge Kent A. Jordan - Initial Pretrial Conference held on 2/21/2020. (Court Reporter Gail Verbano.) (lak) |
| Feb 20, 2020 | 724 | Stipulation (2) Docket Text: STIPULATION and [Proposed] Order Regarding Testimony on Hetero Label at Trial by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Feb 14, 2020 | 723 | Redacted Document (30) Docket Text: REDACTED VERSION of [715] Proposed Pretrial Order by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Feb 12, 2020 | 718 | Redacted Document (25) Docket Text: REDACTED VERSION of [704] Reply Brief, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Feb 12, 2020 | 719 | Redacted Document (26) Docket Text: REDACTED VERSION of [706] Reply Brief, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Feb 12, 2020 | 720 | Redacted Document (10) Docket Text: REDACTED VERSION of [707] Reply Brief by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Feb 12, 2020 | 721 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Supplemental Expert Report of Dr. Paul M. Hoffman on Infringement of U.S. Patent No. 9,187,405 filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Feb 10, 2020 | 716 | Stipulation of Dismissal (4) Docket Text: STIPULATION of Dismissal as to Apotex Inc. and Apotex Corp. by Apotex Corp., Apotex Inc.. (Moore, David) |
| Feb 10, 2020 | 717 | Main Document (2) Docket Text: REDACTED VERSION of [697] Letter, by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Attachments: # (1) Exhibit A)(Haney, Megan) |
| Feb 10, 2020 | 717 | Exhibit A (7) |
| Feb 7, 2020 | 713 | Order (2) Docket Text: ORDER denying Daubert motions [666], [665], and [664]. *See Order for further details*. Signed by Judge Kent A. Jordan on 2/7/2020. (lak) |
| Feb 7, 2020 | 714 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Dr. Paul Hoffman on February 17, 2020 at 9:30 a.m. at the offices of Gibson, Dunn & Crutcher LLP, 200 Park Avenue, New York, NY 10166-0193 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Feb 5, 2020 | 709 | Redacted Document (13) Docket Text: REDACTED VERSION of [693] Answering Brief in Opposition by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan) |
| Feb 5, 2020 | 710 | Redacted Document (13) Docket Text: REDACTED VERSION of [694] Answering Brief in Opposition by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan) |
| Feb 5, 2020 | 711 | Redacted Document (13) Docket Text: REDACTED VERSION of [695] Answering Brief in Opposition by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan) |
| Feb 5, 2020 | 712 | Redacted Document (30) Docket Text: REDACTED VERSION of [696] Declaration, by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan) |
| Feb 4, 2020 | N/A | Telephone Conference (0) Docket Text: Minute Entry for proceedings held before Judge Kent A. Jordan - Telephone Conference held on 2/4/2020. (Court Reporter Lorraine B. Marino.) (mal) |
| Feb 4, 2020 | 708 | Notice (Other) (1) Docket Text: NOTICE of [Notice of Intent to Request Redaction of Transcript of 2/4/20 teleconference which has not yet been docketed] by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc. (Phillips, John) |
| Feb 3, 2020 | 705 | Letter (1) Docket Text: Letter to The Honorable Kent A. Jordan, Circuit Judge from Daniel M. Silver, Esq. - re [704] Reply Brief,. (Silver, Daniel) |
| Jan 31, 2020 | 701 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants' Joint Notice of Prior Art under 35 U.S.C. ยง 282 filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Dorsney, Kenneth) |
| Jan 31, 2020 | 702 | Main Document (3) Docket Text: REDACTED VERSION of [680] Letter by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Attachments: # (1) Exhibits A-B)(Phillips, John) |
| Jan 31, 2020 | 702 | Exhibits A-B (23) |
| Jan 31, 2020 | 703 | Redacted Document (24) Docket Text: REDACTED VERSION of [683] Letter, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jan 30, 2020 | 700 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Radjoka Savic on February 11, 2020 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Jan 29, 2020 | N/A | Set Deadlines (0) Docket Text: ORAL ORDER, A Telephone Conference is set for 2/4/2020 at 10:00 AM in Chambers before Judge Kent A. Jordan. (lak) |
| Jan 28, 2020 | 699 | Letter (1) Docket Text: Letter to The Honorable Kent A. Jordan, Circuit Judge from Daniel M. Silver regarding Teleconference on Defendants' Motion to Strike the Supplemental Expert Reports of Dr. Fred Lublin, M.D. - re [674] MOTION to Strike Supplemental Expert Reports of Dr. Fred Lublin, M.D.. (Silver, Daniel) |
| Jan 27, 2020 | 684 | Redacted Document (24) Docket Text: REDACTED VERSION of [663] Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jan 27, 2020 | 685 | Redacted Document (16) Docket Text: REDACTED VERSION of [664] Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jan 27, 2020 | 686 | Redacted Document (14) Docket Text: REDACTED VERSION of [665] Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jan 27, 2020 | 687 | Redacted Document (14) Docket Text: REDACTED VERSION of [666] Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jan 27, 2020 | 688 | Redacted Document (15) Docket Text: REDACTED VERSION of [667] Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jan 27, 2020 | 689 | Main Document (293) Docket Text: REDACTED VERSION of [668] Declaration,, by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Pt. 2 of 2)(Silver, Daniel) |
| Jan 27, 2020 | 689 | Pt. 2 of 2 (58) |
| Jan 27, 2020 | 690 | Redacted Document (5) Docket Text: REDACTED VERSION of [669] Declaration by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jan 27, 2020 | 691 | Redacted Document (6) Docket Text: REDACTED VERSION of [670] Declaration by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jan 27, 2020 | 692 | Redacted Document (6) Docket Text: REDACTED VERSION of [671] Declaration by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jan 27, 2020 | 698 | Letter (1) Docket Text: Letter to the Honorable Kent A. Jordan from John C. Phillips, Jr. regarding Request for Teleconference on Defendants' Motion to STrike the Supplemental Expert Reports of Dr. Fred Lublin - re [674] MOTION to Strike Supplemental Expert Reports of Dr. Fred Lublin, M.D.. (Phillips, John) |
| Jan 23, 2020 | 681 | Main Document (5) Docket Text: REDACTED VERSION of [675] Letter, by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Attachments: # (1) Exhibits A-E, # (2) Exhibit F, # (3) Exhibit G-H)(Phillips, John) |
| Jan 23, 2020 | 681 | Exhibits A-E (1) |
| Jan 23, 2020 | 681 | Exhibit F (2) |
| Jan 23, 2020 | 681 | Exhibit G-H (1) |
| Jan 23, 2020 | 682 | Main Document (4) Docket Text: REDACTED VERSION of [677] Letter,, by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Attachments: # (1) Exhibits A-E, # (2) Exhibit F)(Phillips, John) |
| Jan 23, 2020 | 682 | Exhibits A-E (1) |
| Jan 23, 2020 | 682 | Exhibit F (14) |
| Jan 21, 2020 | N/A | Telephone Conference (0) Docket Text: Minute Entry for proceedings held before Judge Kent A. Jordan - Telephone Conference held on 1/21/2020. (Court Reporter Lorraine B. Marino.) (mal) |
| Jan 20, 2020 | 678 | Letter (5) Docket Text: Letter to The Honorable Kent A. Jordan from Daniel M. Silver, Esq. regarding Opposition to Defendants' Motion to Strike Novartis's Daubert Motions - re [677] Letter,,. (Silver, Daniel) |
| Jan 17, 2020 | 673 | Order (1) Docket Text: ORDER, A teleconference relating to a discovery dispute has been scheduled for January 21, 2020 at 2:00 p.m. with the undersigned. Counsel for Zydus shall initiate the teleconference call. The parties are further ordered to file simultaneous letters of not more than three (3) pages outlining their position by close of business on January 20, 2020. Signed by Judge Kent A. Jordan on 1/17/2020. (lak) |
| Jan 17, 2020 | 674 | Main Document (2) Docket Text: MOTION to Strike Supplemental Expert Reports of Dr. Fred Lublin, M.D. - filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Attachments: # (1) Text of Proposed Order, # (2) 7.1.1 Statement)(Phillips, John) |
| Jan 17, 2020 | 674 | Text of Proposed Order (1) |
| Jan 17, 2020 | 674 | 7.1.1 Statement (1) |
| Jan 17, 2020 | 676 | Main Document (2) Docket Text: MOTION to Strike [667] Opening Brief in Support, [671] Declaration, [670] Declaration, [666] Opening Brief in Support, [665] Opening Brief in Support, [669] Declaration, [663] Opening Brief in Support, [664] Opening Brief in Support, Defendants' Motion to Strike Five Purported Daubert Motions - filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Attachments: # (1) Text of Proposed Order, # (2) 7.1.1 Certification)(Phillips, John) |
| Jan 17, 2020 | 676 | Text of Proposed Order (1) |
| Jan 17, 2020 | 676 | 7.1.1 Certification (1) |
| Jan 16, 2020 | 672 | Letter (2) Docket Text: Letter to The Honorable Kent A. Jordan from John C. Phillips, Jr. regarding requesting a discovery teleconference. (Phillips, John) |
| Jan 8, 2020 | N/A | Telephone Conference (0) Docket Text: Minute Entry for proceedings held before Judge Kent A. Jordan - Telephone Conference held on 1/8/2020. (Court Reporter Gail Verbano.) (lak) |
| Jan 8, 2020 | 661 | Order (1) Docket Text: ORDER, the parties' Pretrial Order to be filed and two copies delivered to chambers before the close of business on February 7, 2020; and the bench trial shall begin on March 2, 2020, starting 9:00 a.m. Signed by Judge Kent A. Jordan on 1/8/2020. (lak) |
| Jan 8, 2020 | 662 | Stipulation (4) Docket Text: STIPULATION and [Proposed] Order Regarding Novartis's Request for a Permanent Injunction by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jan 3, 2020 | 659 | Main Document (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Christine Ranney, Kyanna Sabanoglu, Shyam Shanker, Sung Bin Lee, and Emil Nachman of Gibson, Dunn & Crutcher LLP - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Certification of Christine Ranney, # (2) Certification of Kyanna Sabanoglu, # (3) Certification of Shyam Shanker, # (4) Certification of Sung Bin Lee, # (5) Certification of Emil Nachman)(Silver, Daniel) |
| Jan 3, 2020 | 659 | Certification of Christine Ranney (1) |
| Jan 3, 2020 | 659 | Certification of Kyanna Sabanoglu (1) |
| Jan 3, 2020 | 659 | Certification of Shyam Shanker (1) |
| Jan 3, 2020 | 659 | Certification of Sung Bin Lee (1) |
| Jan 3, 2020 | 659 | Certification of Emil Nachman (1) |
| Jan 3, 2020 | 660 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Second Supplemental Expert Report of Fred D. Lublin, M.D. Regarding Infringement filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) |
| Dec 30, 2019 | 658 | Order Setting Teleconference (1) Docket Text: ORDER Setting Teleconference: IT IS ORDERED that a teleconference in the above-captioned matter has been scheduled for January 8, 2020 at 2:30 p.m. Counsel for Plaintiff shall initiate the teleconference call. Signed by Judge Kent A. Jordan on 12/30/2019. (amf) |
| Dec 23, 2019 | 657 | Redacted Document (4) Docket Text: REDACTED VERSION of [653] Stipulation and Proposed Order Staying the Case as to Sun Pharmaceutical Industries, Ltd., Sun Pharmaceutical Industries, Inc., and Sun Pharma Global FZE by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Dec 19, 2019 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Reassigned to Judge Kent A. Jordan of the United States Court of Appeals for the Third Circuit. Please include the initials of the Judge (KAJ) after the case number on all documents filed. (rjb) |
| Dec 19, 2019 | 656 | Order (1) Docket Text: ORDER: DESIGNATION OF CIRCUIT JUDGE TO HOLD A DISTRICT COURT WITHIN THE CIRCUIT, designating and assigning the Honorable Kent A. Jordan of the United States Court of Appeals for the Third Circuit. Signed by Judge D. Brooks Smith, Chief Judge of the United States Court of Appeals for the Third Circuit on 12/19/2019. (rjb) |
| Dec 18, 2019 | 655 | Redacted Document (4) Docket Text: REDACTED VERSION of [652] Proposed Consent Judgment by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Dec 17, 2019 | 654 | Main Document (1) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney August Melcher - filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Attachments: # (1) Certification of August Melcher)(Haney, Megan) |
| Dec 17, 2019 | 654 | Certification of August Melcher (1) |
| Dec 11, 2019 | 651 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Supplemental Expert Report of Fred D. Lublin, M.D. Regarding Infringement filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Dec 4, 2019 | 647 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Supplemental Expert Report of William J. Jusko, Ph.D. on the Validity of U.S. Patent No. 9,187,405 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Dec 4, 2019 | 648 | Notice to Take Deposition (3) Docket Text: NOTICE to Take Deposition of Lawrence Steinman, M.D. on December 17, 2019 filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Dec 4, 2019 | 649 | Notice to Take Deposition (3) Docket Text: NOTICE to Take Deposition of Fred D. Lublin, M.D. on December 13, 2019 filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Dec 4, 2019 | 650 | Notice to Take Deposition (3) Docket Text: NOTICE to Take Deposition of William J. Jusko, Ph.D. on December 9, 2019 filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Dec 2, 2019 | 645 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Robert Fujinami on December 19, 2019 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Dec 2, 2019 | 646 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Paul M. Hoffman filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Nov 21, 2019 | 644 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Radojka Savic on November 22, 2019 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Nov 8, 2019 | 643 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Reply Expert Report of Dr. Robert Fujinami on Secondary Considerations Related to U.S. Patent No. 9,187,405; (2) Reply Expert Report of Dr. Paul M. Hoffman on Secondary Considerations Related to U.S. Patent No. 9,187,405; and (3) Reply Declaration of Dr. Radojka Savic on Invalidity of U.S. Patent No. 9,187,405 filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Oct 17, 2019 | 642 | Notice Requesting Removal of Co-Counsel (2) Docket Text: NOTICE requesting Clerk to remove Mary Procaccio-Flowers of Wilson Sonsini Goodrich & Rosati as co-counsel. Reason for request: no longer working on the matter. (Palapura, Bindu) |
| Oct 4, 2019 | 641 | Notice Requesting Removal of Co-Counsel (1) Docket Text: NOTICE requesting Clerk to remove Charles A. Weiss as co-counsel.. (Dorsney, Kenneth) |
| Sep 30, 2019 | 640 | Notice (Other) (1) Docket Text: NOTICE of Change of Law Firm Affiliation by Bionpharma Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc. (Dorsney, Kenneth) |
| Sep 27, 2019 | 638 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Rebuttal Expert Report of Dr. Paul M. Hoffman on Infringement of U.S. Patent No. 9,187,405 filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Sep 27, 2019 | 639 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) Second Expert Report of Fred D. Lublin, M.D.; (2) First Expert Report of William J Jusko, Ph.D.; and (3) First Expert Report of Lawrence Steinman, M.D. filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Sep 6, 2019 | N/A | Order (0) Docket Text: ORAL ORDER: In light of the stay of this case as to Mylan, IT IS HEREBY ORDERED that the following motions are DENIED WITHOUT PREJUDICE TO RENEW upon the lifting of the stay: D.I. 522, 533. ORDERED by Judge Leonard P. Stark on 9/6/19. (ntl) |
| Sep 4, 2019 | 634 | Redacted Transcript (54) Docket Text: Redaction of [308] Transcript. Telephone Conference held on December 21, 2018 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone (302) 573-6360. (bpg) |
| Sep 4, 2019 | 635 | Stipulation (4) Docket Text: STIPULATION and [Proposed] Order Staying the Case as to Dr. Reddy's by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Aug 22, 2019 | 633 | Notice Requesting Removal of Co-Counsel (4) Docket Text: NOTICE requesting Clerk to remove Forrest M. McClellen as co-counsel.. (Poff, Adam) |
| Aug 9, 2019 | 632 | Statement (2) Docket Text: STATEMENT re [629] Order Unsecured Bond for Preliminary Injunction Order by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Aug 7, 2019 | 631 | Notice of Service (4) Docket Text: NOTICE OF SERVICE of Novartiss Amended Responses to Defendants First Set of Joint Requests for Admission (Nos. 1, 3-7) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Aug 5, 2019 | 630 | Redacted Document (30) Docket Text: REDACTED VERSION of [627] Exhibit to a Document by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Aug 1, 2019 | 628 | Order (1) Docket Text: ORDER re [626] MOTION to Redact [580] Transcript, [581] Transcript filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 8/1/19. (ntl) |
| Aug 1, 2019 | 629 | Order (2) Docket Text: ORDER ON PRELIMINARY INJUNCTION re [357] MOTION for Preliminary Injunction filed by Novartis Pharmaceuticals Corporation, [583] Memorandum Order. Signed by Judge Leonard P. Stark on 8/1/19. (ntl) |
| Jul 29, 2019 | 626 | Main Document (4) Docket Text: MOTION to Redact [580] Transcript,, [581] Transcript - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit B, # (2) Text of Proposed Order)(Silver, Daniel) |
| Jul 29, 2019 | 626 | Exhibit B (47) |
| Jul 29, 2019 | 626 | Text of Proposed Order (1) |
| Jul 26, 2019 | 625 | Proposed Order (2) Docket Text: PROPOSED ORDER on Preliminary Injunction by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jul 23, 2019 | 620 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Opening Expert Report of Dr. Paul M. Hoffman On Invalidity of U.S. Patent No. 9,187,405 and Opening Expert Report of Dr. Robert Fujinami on EAE and U.S. Patent No. 9,187,405 filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Jul 23, 2019 | 621 | Redacted Document (7) Docket Text: REDACTED VERSION of [612] Letter by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jul 23, 2019 | 622 | Redacted Document (24) Docket Text: REDACTED VERSION of [613] Declaration by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jul 23, 2019 | 623 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Declaration of Dr. Radojka Savic on Invalidity of U.S. Patent No. 9,187,405 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Jul 22, 2019 | 618 | Stipulation (3) Docket Text: STIPULATION Extend Deadline for Parties to Submit Redaction Requests Regarding the June 21, 2019 Preliminary Injunction Hearing to July 29, 2019 by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jul 22, 2019 | 619 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) First Expert Report of Fred D. Lublin, M.D., and (2) Expert Report of Christopher A. Vellturo, Ph.D. filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Jul 19, 2019 | 617 | Main Document (7) Docket Text: REDACTED VERSION of [610] Letter, by HEC Pharm Co., Ltd., HEC Pharm USA Inc.. (Attachments: # (1) Declaration, # (2) Exhibit A-6)(Stamoulis, Stamatios) |
| Jul 19, 2019 | 617 | Declaration (4) |
| Jul 19, 2019 | 617 | Exhibit A-6 (4) |
| Jul 15, 2019 | 614 | Redacted Document (7) Docket Text: REDACTED VERSION of [608] Stipulation by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jul 15, 2019 | 616 | Stipulation to EXTEND Time (3) Docket Text: STIPULATION TO EXTEND TIME the Deadline for the Parties to Submit Redaction Request regarding June 21, 2019 Preliminary Injunction Hearing to July 22, 2019 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jul 10, 2019 | 609 | Redacted Document (5) Docket Text: REDACTED VERSION of [604] Stipulation by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jul 10, 2019 | 611 | Letter (1) Docket Text: Letter to Honorable Leonard P. Stark from Daniel M. Silver regarding Discovery Issues - re [606] Order,,. (Joyce, Alexandra) |
| Jul 3, 2019 | 605 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.'s Objections and Responses to Plaintiff's First Set of Requests for Admission [Nos. 1-9] filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Ormerod, Eve) |
| Jul 2, 2019 | 591 | Redacted Document (10) Docket Text: REDACTED VERSION of [119] Opening Brief in Support Of Mylan Pharmaceuticals Inc.'s Motion To Dismiss For Improper Venue by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
| Jul 2, 2019 | 592 | Main Document (4) Docket Text: REDACTED VERSION of [120] Declaration of Keith Meckstroth by Mylan Pharmaceuticals, Inc.. (Attachments: # (1) Exhibit 1)(Ewing, Alexandra) |
| Jul 2, 2019 | 592 | Exhibit 1 (1) |
| Jul 2, 2019 | 593 | Redacted Document (11) Docket Text: REDACTED VERSION of [206] Reply Brief in Support of Mylan Pharmaceuticals Inc.'s Motion to Dismiss for Improper Venue by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
| Jul 2, 2019 | 594 | Main Document (3) Docket Text: REDACTED VERSION of [207] Declaration of Brandon M. White by Mylan Pharmaceuticals, Inc.. (Attachments: # (1) Exhibit 1-2)(Ewing, Alexandra) |
| Jul 2, 2019 | 594 | Exhibit 1-2 (9) |
| Jul 2, 2019 | 595 | Redacted Document (4) Docket Text: REDACTED VERSION of [219] Letter, to The Honorable Leonard P. Stark from Frederick L. Cottrell, III regarding supplemental letter brief by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
| Jul 2, 2019 | 596 | Redacted Document (3) Docket Text: REDACTED VERSION of [224] Letter to The Honorable Leonard P. Stark from Frederick L. Cottrell, III regarding response to Novartis's letter of October 25, 2018 by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
| Jul 2, 2019 | 597 | Redacted Document (4) Docket Text: REDACTED VERSION of [296] Letter to The Honorable Leonard P. Stark from Frederick L. Cottrell, III regarding Regarding Mylan Pharmaceuticals, Inc.'s Response to Novartis Concerning Redaction Dispute by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
| Jul 2, 2019 | 598 | Main Document (4) Docket Text: REDACTED VERSION of [333] MOTION to Seal Limited Sections of Transcript by Mylan Pharmaceuticals, Inc.. (Attachments: # (1) Proposed Order, # (2) Exhibit A, # (3) Exhibit B)(Ewing, Alexandra) |
| Jul 2, 2019 | 598 | Proposed Order (1) |
| Jul 2, 2019 | 598 | Exhibit A (47) |
| Jul 2, 2019 | 598 | Exhibit B (47) |
| Jul 2, 2019 | 599 | Redacted Document (25) Docket Text: REDACTED VERSION of [163] Answering Brief in Opposition, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jul 2, 2019 | 600 | Redacted Document (30) Docket Text: REDACTED VERSION of [220] Letter, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jul 2, 2019 | 601 | Redacted Document (4) Docket Text: REDACTED VERSION of [225] Letter by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jul 2, 2019 | 602 | Redacted Document (14) Docket Text: REDACTED VERSION of [286] Letter by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jul 2, 2019 | 603 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Amended Privilege Log filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Jul 1, 2019 | 589 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.'s Privilege Log filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Ormerod, Eve) |
| Jul 1, 2019 | 590 | Redacted Document (4) Docket Text: REDACTED VERSION of [582] Proposed Consent Judgment by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jun 28, 2019 | 588 | Status Report (2) Docket Text: Joint STATUS REPORT by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jun 27, 2019 | 585 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Hetero's responses to Plaintiff's First Set of Requests for Admission to Hetero (Nos. 1-9) filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Dorsney, Kenneth) |
| Jun 27, 2019 | 586 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Novartis's First Set of Requests for Admission filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Jun 27, 2019 | 587 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Responses to Plaintiffs First Set of Requests for Admission Nos. 1-9 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Jun 25, 2019 | 584 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME to file public copies of documents pursuant to Court's Memorandum Order (DI. 575) to July 2, 2019 - filed by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
| Jun 24, 2019 | 583 | Memorandum and Order (9) Docket Text: MEMORANDUM ORDER re [357] MOTION for Preliminary Injunction filed by Novartis Pharmaceuticals Corporation is GRANTED. Signed by Judge Leonard P. Stark on 6/24/19. (ntl) |
| Jun 21, 2019 | N/A | Evidentiary Hearing (0) Docket Text: Minute Entry for proceedings held before Judge Leonard P. Stark - Preliminary Injunction Hearing held on 6/21/2019. (Court Reporter B. Gaffigan.) (ntl) |
| Jun 20, 2019 | 578 | Redacted Document (10) Docket Text: REDACTED VERSION of [574] Notice (Other) by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jun 19, 2019 | 576 | Notice of Appearance (1) Docket Text: NOTICE of Appearance by Jennifer M. Rutter on behalf of Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd. (Rutter, Jennifer) |
| Jun 19, 2019 | 577 | Stipulation to EXTEND Time (4) Docket Text: STIPULATION TO EXTEND TIME Various Deadlines to Various Dates - filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan) |
| Jun 17, 2019 | 575 | Memorandum and Order (13) Docket Text: MEMORANDUM ORDER re [118] MOTION to Dismiss for Improper Venue filed by Mylan Pharmaceuticals, Inc. is GRANTED and Plaintiff's request for discovery and to file an amended complaint is DENIED. Signed by Judge Leonard P. Stark on 6/17/19. (ntl) |
| Jun 12, 2019 | 568 | Redacted Document (4) Docket Text: REDACTED VERSION of [562] Proposed Consent Judgment by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jun 12, 2019 | 569 | Redacted Document (27) Docket Text: REDACTED VERSION of [564] Answering Brief in Opposition, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jun 12, 2019 | 570 | Redacted Document (12) Docket Text: REDACTED VERSION of [565] Declaration by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jun 12, 2019 | 571 | Reply Brief (16) Docket Text: REPLY BRIEF re [522] MOTION to Dismiss for Failure to State a Claim Under Rule 12(b)(6) filed by Mylan Pharmaceuticals, Inc.. (Cottrell, Frederick) |
| Jun 12, 2019 | 572 | Main Document (3) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding June 21, 2019 Preliminary Injunction Hearing - re [332] Order,,,,,, Set Hearings,,,,,. (Attachments: # (1) [Proposed] Order Regarding June 21, 2019 Preliminary Injunction)(Silver, Daniel) |
| Jun 12, 2019 | 572 | [Proposed] Order Regarding June 21, 2019 Preliminary Injunction (3) |
| Jun 12, 2019 | 573 | Letter (2) Docket Text: Letter to the Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Defendants' Allocation For the Preliminary Injunction Hearing - re [332] Order,,,,,, Set Hearings,,,,,. (Phillips, John) |
| Jun 11, 2019 | 567 | Stipulation (4) Docket Text: STIPULATION and [Proposed] Order to Extend the Time the deadline for the parties to submit letters to the Court regarding the June 21, 2019 preliminary injunction hearing re [332] Order,,,,,, Set Hearings,,,,, to June 12, 2019 by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jun 7, 2019 | 566 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Privilege Log filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Jun 5, 2019 | 561 | Memorandum Opinion (13) Docket Text: MEMORANDUM OPINION re claim construction. Signed by Judge Leonard P. Stark on 6/5/19. (ntl) |
| Jun 5, 2019 | 563 | Order (2) Docket Text: ORDER re [561] Memorandum Opinion regarding claim construction. Signed by Judge Leonard P. Stark on 6/5/19. (ntl) |
| Jun 4, 2019 | 558 | Notice of Service (6) Docket Text: NOTICE OF SERVICE of Plaintiff's First Amended Privilege Log filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Jun 4, 2019 | 559 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Accord Healthcare, Inc.'s Privilege Log filed by Accord Healthcare Inc..(Ormerod, Eve) |
| Jun 4, 2019 | 560 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.'s: (1) Fourth Supplemental Objections and Responses to Plaintiff's First Set of Common Interrogatories to All Defendants [Nos. 1-7]; (2) Supplemental Objections and Responses to Plaintiff's Second Set of Common Interrogatories to all Defendants [No. 8]; and (3) Supplemental Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) filed by Mylan Pharmaceuticals, Inc..(Rawnsley, Jason) |
| Jun 3, 2019 | 554 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.'s Privilege Log filed by Mylan Pharmaceuticals, Inc..(Rawnsley, Jason) |
| Jun 3, 2019 | 555 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Privilege Log filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Jun 3, 2019 | 556 | Letter (2) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Discovery Teleconference. (Silver, Daniel) |
| Jun 3, 2019 | 557 | Notice of Service (6) Docket Text: NOTICE OF SERVICE of Novartiss Responses to Defendants First Set of Joint Requests for Admission (Nos. 1-22) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| May 31, 2019 | 552 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Hetero's Privilege Log filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Dorsney, Kenneth) |
| May 31, 2019 | 553 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Privilege Log filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Weinblatt, Richard) |
| May 30, 2019 | 550 | Letter (3) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Responsive Letter - re [546] Letter,. (Silver, Daniel) |
| May 30, 2019 | 551 | Stipulation (5) Docket Text: STIPULATION and [Proposed] Order by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 29, 2019 | 546 | Letter (5) Docket Text: Letter to The Honorable Leonard P. Stark from Frederick L. Cottrell, III regarding Plaintiff Novartis Pharm. Corp.'s Motion to Strike Mylan Pharmaceuticals, Inc.'s Motion to Dismiss - re [534] Letter, [535] Declaration, [533] Emergency MOTION to Strike [523] Opening Brief in Support, [522] MOTION to Dismiss for Failure to State a Claim . (Cottrell, Frederick) |
| May 29, 2019 | 547 | Notice of Service (8) Docket Text: NOTICE OF SERVICE of Plaintiff's First Set of Requests for Admission to Defendants filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| May 29, 2019 | 548 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME the Deadline for Plaintiff to File its Opposition to Mylans Motion to Dismiss Under Rule 12(b)(6) to June 5, 2019 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 29, 2019 | 549 | Reply to Response to Motion (3) Docket Text: REPLY to Response to Motion re [513] MOTION Novartis's Motion for Submission of Supplemental Paper in Support of Its Claim Construction Answering Brief filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 28, 2019 | 539 | Main Document (2) Docket Text: REDACTED VERSION of [524] Declaration, of Jason Rawnsley by Mylan Pharmaceuticals, Inc.. (Attachments: # (1) Exhibit 1)(Ewing, Alexandra) |
| May 28, 2019 | 539 | Exhibit 1 (1) |
| May 28, 2019 | 540 | Notice to Take Deposition (4) Docket Text: NOTICE to Take Deposition of Arvashni Seeripat on May 30, 2019 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| May 28, 2019 | 541 | Notice to Take Deposition (4) Docket Text: NOTICE to Take Deposition of Arvashni Seeripat on May 30, 2019 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| May 28, 2019 | 542 | Notice to Take Deposition (4) Docket Text: NOTICE to Take Deposition of Dr. Peter Calabresi on June 7, 2019 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| May 28, 2019 | 543 | Notice to Take Deposition (4) Docket Text: NOTICE to Take Deposition of Dr. Christopher Vellturo on June 13, 2019 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| May 28, 2019 | 544 | Notice to Take Deposition (4) Docket Text: NOTICE to Take Deposition of Peter Waibel on June 11, 2019 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| May 28, 2019 | 545 | Notice to Take Deposition (4) Docket Text: NOTICE to Take Deposition of Peter Waibel on June 11, 2019 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| May 24, 2019 | 536 | Main Document (2) Docket Text: REDACTED VERSION of [524] Declaration, of Jason J. Rawnsley by Mylan Pharmaceuticals, Inc.. (Attachments: # (1) Exhibit 1)(Ewing, Alexandra) |
| May 24, 2019 | 536 | Exhibit 1 (1) |
| May 24, 2019 | 537 | Memorandum in Opposition (5) Docket Text: MEMORANDUM in Opposition re [513] MOTION Novartis's Motion for Submission of Supplemental Paper in Support of Its Claim Construction Answering Brief filed by Mylan Pharmaceuticals, Inc..Reply Brief due date per Local Rules is 5/31/2019. (Cottrell, Frederick) |
| May 24, 2019 | 538 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Radhika Dasari on June 11, 2019 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| May 23, 2019 | 533 | Main Document (2) Docket Text: Emergency MOTION to Strike [523] Opening Brief in Support, [522] MOTION to Dismiss for Failure to State a Claim - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Text of Proposed Order, # (2) Text of Proposed Order, # (3) Rule 7.1.1 Certification)(Silver, Daniel) |
| May 23, 2019 | 533 | Text of Proposed Order (1) |
| May 23, 2019 | 533 | Text of Proposed Order (1) |
| May 23, 2019 | 533 | Rule 7.1.1 Certification (1) |
| May 23, 2019 | 534 | Letter (3) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esquire regarding Novartis's Emergency Motion to Stike - re [533] Emergency MOTION to Strike [523] Opening Brief in Support, [522] MOTION to Dismiss for Failure to State a Claim . (Silver, Daniel) |
| May 23, 2019 | 535 | Declaration (3) Docket Text: DECLARATION re [534] Letter, [533] Emergency MOTION to Strike [523] Opening Brief in Support, [522] MOTION to Dismiss for Failure to State a Claim Declaration of Daniel M. Silver, Esq. by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 22, 2019 | 526 | Redacted Document (20) Docket Text: REDACTED VERSION of [514] Reply Brief by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 22, 2019 | 527 | Redacted Document (17) Docket Text: REDACTED VERSION of [515] Declaration of Fred Lublin by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 22, 2019 | 528 | Redacted Document (9) Docket Text: REDACTED VERSION of [516] Declaration of Peter Waibel by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 22, 2019 | 529 | Redacted Document (30) Docket Text: REDACTED VERSION of [517] Declaration of Christopher Vellturo by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 22, 2019 | 530 | Redacted Document (30) Docket Text: REDACTED VERSION of [518] Declaration, of Robert Trenchard by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 22, 2019 | 531 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Dr. Vijay Raghavan on June 4, 2019 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| May 22, 2019 | 532 | Motion for Leave to Appear Pro Hac Vice (4) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Maria A. Stubbings - filed by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
| May 20, 2019 | 521 | Notice of Service (6) Docket Text: NOTICE OF SERVICE of Plaintiff's Privilege Log filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| May 20, 2019 | 522 | Main Document (2) Docket Text: MOTION to Dismiss for Failure to State a Claim - filed by Mylan Pharmaceuticals, Inc.. (Attachments: # (1) Text of Proposed Order)(Cottrell, Frederick) |
| May 20, 2019 | 522 | Text of Proposed Order (1) |
| May 20, 2019 | 523 | Opening Brief in Support (23) Docket Text: OPENING BRIEF in Support re [522] MOTION to Dismiss for Failure to State a Claim filed by Mylan Pharmaceuticals, Inc..Answering Brief/Response due date per Local Rules is 6/3/2019. (Cottrell, Frederick) |
| May 20, 2019 | 525 | Request for Oral Argument (2) Docket Text: REQUEST for Oral Argument by Mylan Pharmaceuticals, Inc. re [522] MOTION to Dismiss for Failure to State a Claim . (Cottrell, Frederick) |
| May 17, 2019 | 520 | Redacted Document (16) Docket Text: REDACTED VERSION of [513] MOTION Novartis's Motion for Submission of Supplemental Paper in Support of Its Claim Construction Answering Brief by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 15, 2019 | 519 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Supplemental Response to Plaintiffs First Set of Common Interrogatories filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| May 10, 2019 | 512 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Alpesh Pathak on May 30, 2019 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| May 9, 2019 | 511 | Stipulation (4) Docket Text: STIPULATION and [Proposed] Order Staying Claims Against Prinston by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| May 7, 2019 | 510 | Letter (5) Docket Text: Letter to the Honorable Leonard P. Stark from Stamatios Stamoulis regarding Requesting a Discovery Dispute Conference. (Stamoulis, Stamatios) |
| May 6, 2019 | 509 | Letter (2) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Request for a Discovery Conference regarding discovery dispute related to June 21, 2019 preliminary injunction hearing. (Silver, Daniel) |
| May 3, 2019 | 507 | Letter (1) Docket Text: Letter to the Honorable Leonard P. Stark from Jason J. Rawnsley (#5379) regarding Mylans request for discovery dispute teleconference. (Rawnsley, Jason) |
| May 3, 2019 | 508 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of First Set of Joint Requests for Admission filed by Mylan Pharmaceuticals, Inc..(Rawnsley, Jason) |
| May 2, 2019 | 506 | Notice of Appearance (1) Docket Text: NOTICE of Appearance by Alexandra M. Joyce on behalf of Novartis Pharmaceuticals Corporation (Joyce, Alexandra) |
| May 1, 2019 | 504 | Redacted Document (5) Docket Text: REDACTED VERSION of [495] Letter by HEC Pharm Co., Ltd., HEC Pharm USA Inc.. (Stamoulis, Stamatios) |
| May 1, 2019 | 505 | Main Document (3) Docket Text: REDACTED VERSION of [496] Declaration by HEC Pharm Co., Ltd., HEC Pharm USA Inc.. (Attachments: # (1) Redacted Exhibit A, # (2) Redacted Exhibit B, # (3) Exhibit C)(Stamoulis, Stamatios) |
| May 1, 2019 | 505 | Redacted Exhibit A (1) |
| May 1, 2019 | 505 | Redacted Exhibit B (1) |
| May 1, 2019 | 505 | Exhibit C (11) |
| Apr 29, 2019 | 499 | Redacted Document (9) Docket Text: REDACTED VERSION of [489] Letter by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Apr 29, 2019 | 500 | Redacted Document (23) Docket Text: REDACTED VERSION of [490] Declaration by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Apr 29, 2019 | 501 | Notice to Take Deposition (3) Docket Text: NOTICE to Take Deposition of Christian Schnell on May 24, 2019 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Apr 29, 2019 | 502 | Notice to Take Deposition (3) Docket Text: NOTICE to Take Deposition of Peter Hiestand on May 10, 2019 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Apr 29, 2019 | 503 | Notice to Take Deposition (3) Docket Text: NOTICE to Take Deposition of Robert Schmouder on May 17, 2019 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Apr 25, 2019 | N/A | Order Cancelling Deadline (0) Docket Text: ORAL ORDER: Having reviewed the parties' letters regarding a discovery dispute (D.I. 489, 495), IT IS HEREBY ORDERED that HEC shall produce responsive, non-privileged documents in the possession of CANDA HEC-1 LLC ("CANDA HEC"), and supplement its responses to interrogatories with any information in the possession of CANDA HEC, no later than May 15, 2019. The Court finds that Novartis has met its burden to show that Defendant HEC has sufficient control (within the meaning of Rule 34) over the relevant and responsive discovery sought by Novartis, based on at least the following: HEC's rights under Section 11.09 of its agreement with CANDA HEC, CANDA HEC's responsibility for managing the instant litigation and for marketing HEC's proposed generic product (if it is launched), and CANDA HEC's right to share in proceeds that may be derived from HEC's proposed generic product. See Robert Bosch LLC v. Alberee Prod., Inc., 2017 WL 376270, at *3 (D. Del. Jan. 24, 2017) ("The Court's finding as to BLLC's control is based on, among other things, BLLC's ability to secure from BGmbH documents that BLLC appears to have viewed as helpful to BLLC's litigation position during this litigation [and that] BLLC and BGmbH are parties to a joint venture agreement [as well as the] close interactions between BLLC and BGmbH with respect to wiper blade products."). The Court is unpersuaded by HEC's contentions that this dispute constitutes an "improper and wasteful use of the Court's time and resources" or that Plaintiff's failure to seek information by means of a Rule 45 subpoena should cause the Court to make a different finding with respect to HEC's control. IT IS FURTHER ORDERED that the discovery teleconference scheduled for tomorrow is CANCELLED. ORDERED by Judge Leonard P. Stark on 4/25/19. (ntl) |
| Apr 25, 2019 | 498 | Transcript (63) Docket Text: Official Transcript of Claim Construction Hearing held on April 23, 2019 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date it may be obtained through PACER. Redaction Request due 5/16/2019. Redacted Transcript Deadline set for 5/28/2019. Release of Transcript Restriction set for 7/24/2019. (bpg) (Main Document 498 replaced on 5/2/2019) (ntl). |
| Apr 24, 2019 | 493 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Paul M. Hoffman filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Apr 24, 2019 | 494 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Ivan T. Hofmann on May 1, 2019 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Apr 23, 2019 | N/A | Markman Hearing (0) Docket Text: Minute Entry for proceedings held before Judge Leonard P. Stark - Markman Hearing held on 4/23/2019. (Court Reporter B. Gaffigan.) (ntl) |
| Apr 23, 2019 | 491 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Aurobindo's First Supplemental Response to Plaintiff's 30(b)(6) Deposition Notice to Aurobindo filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
| Apr 23, 2019 | 492 | Main Document (9) Docket Text: REDACTED VERSION of [482] Statement by Accord Healthcare Inc., Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc., Cadila Healthcare Limited, Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., HEC Pharm Co., Ltd., HEC Pharm USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Mylan Pharmaceuticals, Inc., Prinston Pharmaceutical Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Zydus Pharmaceuticals (USA) Inc.. (Attachments: # (1) Exhibit A)(Stamoulis, Stamatios) |
| Apr 23, 2019 | 492 | Exhibit A (22) |
| Apr 22, 2019 | 488 | Notice of Appearance (1) Docket Text: NOTICE of Appearance by Sara M. Metzler on behalf of Breckenridge Pharmaceutical, Inc., Standard Chemical & Pharmaceutical Co., Ltd. (Metzler, Sara) |
| Apr 18, 2019 | N/A | Order Setting Teleconference (0) Docket Text: ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter (D.I. 382), IT IS HEREBY ORDERED that a teleconference is scheduled for April 26, 2019 at 1:15 p.m. Counsel for the party seeking relief shall initiate the teleconference call to 302-573-4571. IT IS FURTHER ORDERED that not later than April 22, 2019, any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than April 24, 2019, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Each party shall submit to the Court two (2) courtesy copies of its discovery letter and any attachments. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Leonard P. Stark on 4/18/19. (ntl) |
| Apr 16, 2019 | 469 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Christine Walton on April 18, 2019 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Apr 16, 2019 | 470 | Redacted Document (30) Docket Text: REDACTED VERSION of [458] Answering Brief in Opposition Defendants' Opposition to Novartis's Motion For Preliminary Injunction by Mylan Pharmaceuticals, Inc.. (Cottrell, Frederick) |
| Apr 16, 2019 | 471 | Redacted Document (30) Docket Text: REDACTED VERSION of [459] Declaration of Ivan T. Hofmann by Mylan Pharmaceuticals, Inc.. (Cottrell, Frederick) |
| Apr 16, 2019 | 472 | Redacted Document (30) Docket Text: REDACTED VERSION of [460] Declaration of Dr. Paul M. Hoffman on Invalidity of U.S. Patent No. 9,187,405 by Mylan Pharmaceuticals, Inc.. (Cottrell, Frederick) |
| Apr 16, 2019 | 473 | Main Document (17) Docket Text: REDACTED VERSION of [461] Declaration of Bryan D. Beel (Volume 1 of 5) by Mylan Pharmaceuticals, Inc.. (Attachments: # (1) Exhibit 1-25, # (2) Exhibit 26-50)(Cottrell, Frederick) |
| Apr 16, 2019 | 473 | Exhibit 1-25 (496) |
| Apr 16, 2019 | 473 | Exhibit 26-50 (148) |
| Apr 16, 2019 | 474 | Redacted Document (30) Docket Text: REDACTED VERSION of [462] Exhibit to a Document Exhibits to Declaration of Bryan D. Beel (Volume 2 of 5) by Mylan Pharmaceuticals, Inc.. (Cottrell, Frederick) |
| Apr 16, 2019 | 475 | Redacted Document (30) Docket Text: REDACTED VERSION of [463] Exhibit to a Document Exhibits to Declaration of Bryan D. Beel (Volume 3 of 5) by Mylan Pharmaceuticals, Inc.. (Cottrell, Frederick) |
| Apr 16, 2019 | 476 | Redacted Document (30) Docket Text: REDACTED VERSION of [464] Exhibit to a Document Exhibits to Declaration of Bryan D. Beel (Volume 4 of 5) by Mylan Pharmaceuticals, Inc.. (Cottrell, Frederick) |
| Apr 16, 2019 | 477 | Redacted Document (30) Docket Text: REDACTED VERSION of [465] Exhibit to a Document Exhibits to Declaration of Bryan D. Beel (Volume 5 of 5) by Mylan Pharmaceuticals, Inc.. (Cottrell, Frederick) |
| Apr 16, 2019 | 478 | Letter (1) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Markman Hearing. (Silver, Daniel) |
| Apr 16, 2019 | 480 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Defendants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.'s Objections and Responses to Novartis' Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Ormerod, Eve) |
| Apr 16, 2019 | 484 | Claim Construction Answering Brief (27) Docket Text: CLAIM CONSTRUCTION ANSWERING BRIEF by Defendants filed by Mylan Pharmaceuticals, Inc.. (Cottrell, Frederick) |
| Apr 16, 2019 | 485 | Main Document (2) Docket Text: DECLARATION re [484] Claim Construction Answering Brief (of Bryan D. Beel) by Mylan Pharmaceuticals, Inc.. (Attachments: # (1) Exhibit 1)(Cottrell, Frederick) |
| Apr 16, 2019 | 485 | Exhibit 1 (7) |
| Apr 15, 2019 | 468 | Notice (Other) (2) Docket Text: NOTICE of Change of Firm Affiliation - Alan H. Pollack, Louis H. Weinstein, and James P. Barabas by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd. (Ormerod, Eve) |
| Apr 11, 2019 | 466 | Notice to Take Deposition (3) Docket Text: NOTICE to Take Deposition of Nicole Cornett on April 17, 2019 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Apr 11, 2019 | 467 | Notice to Take Deposition (3) Docket Text: NOTICE to Take Deposition of Shreeram Aradhye on April 18, 2019 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Apr 5, 2019 | 457 | Redacted Document (12) Docket Text: REDACTED VERSION of [455] Notice (Other) by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
| Apr 2, 2019 | 456 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Defendant Accord Healthcare, Inc.'s Objections and Responses to Plaintiff's Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Accord Healthcare Inc..(Ormerod, Eve) |
| Mar 27, 2019 | 454 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Vijay Nasare on April 9, 2019 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Mar 21, 2019 | 453 | Letter (1) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Discovery Conference Request - re [419] Letter. (Silver, Daniel) |
| Mar 20, 2019 | 451 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Aurobindo's Objections and Responses to Plaintiff's 30(b)(6) Deposition Notice to Aurobindo filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
| Mar 20, 2019 | 452 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Hetero's Objections and Responses to Plaintiff's 30(b)(6) Deposition Notice filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Dorsney, Kenneth) |
| Mar 19, 2019 | 446 | Redacted Document (30) Docket Text: REDACTED VERSION of [426] Claim Construction Opening Brief by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Mar 19, 2019 | 447 | Redacted Document (29) Docket Text: REDACTED VERSION of [427] Declaration by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Mar 19, 2019 | 448 | Redacted Document (30) Docket Text: REDACTED VERSION of [428] Declaration by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Mar 19, 2019 | 449 | Main Document (14) Docket Text: REDACTED VERSION of [430] Declaration,, by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit 1-5, # (2) Exhibit 6 Pt. 1, # (3) Exhibit 6 Pt. 2, # (4) Exhibit 7-9, # (5) Exhibit 10 Pt. 1, # (6) Exhibit 10 Pt. 2, # (7) Exhibit 11-14, # (8) Exhibit 15 Pt. 1, # (9) Exhibit 15 Pt. 2, # (10) Exhibit 16-19, # (11) Exhibit 20, # (12) Exhibit 21-27, # (13) Exhibit 28-29, # (14) Exhibit 30, # (15) Exhibit 31-39, # (16) Exhibit 40-41, # (17) Exhibit 42-43, # (18) Exhibit 44-51, # (19) Exhibit 52-53)(Silver, Daniel) |
| Mar 19, 2019 | 449 | Exhibit 1-5 (69) |
| Mar 19, 2019 | 449 | Exhibit 6 Pt. 1 (84) |
| Mar 19, 2019 | 449 | Exhibit 6 Pt. 2 (66) |
| Mar 19, 2019 | 449 | Exhibit 7-9 (45) |
| Mar 19, 2019 | 449 | Exhibit 10 Pt. 1 (39) |
| Mar 19, 2019 | 449 | Exhibit 10 Pt. 2 (24) |
| Mar 19, 2019 | 449 | Exhibit 11-14 (39) |
| Mar 19, 2019 | 449 | Exhibit 15 Pt. 1 (197) |
| Mar 19, 2019 | 449 | Exhibit 15 Pt. 2 (150) |
| Mar 19, 2019 | 449 | Exhibit 16-19 (46) |
| Mar 19, 2019 | 449 | Exhibit 20 (2) |
| Mar 19, 2019 | 449 | Exhibit 21-27 (75) |
| Mar 19, 2019 | 449 | Exhibit 28-29 (14) |
| Mar 19, 2019 | 449 | Exhibit 30 (54) |
| Mar 19, 2019 | 449 | Exhibit 31-39 (75) |
| Mar 19, 2019 | 449 | Exhibit 40-41 (109) |
| Mar 19, 2019 | 449 | Exhibit 42-43 (120) |
| Mar 19, 2019 | 449 | Exhibit 44-51 (97) |
| Mar 19, 2019 | 449 | Exhibit 52-53 (72) |
| Mar 19, 2019 | 450 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Kevin Kong on March 27, 2019 at 9:30 a.m. at the offices of Kirkland & Ellis LLP, 601 Lexington Avenue, New York, NY 10022-4611 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Mar 15, 2019 | 445 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Bradley Davis on March 21, 2019 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Mar 14, 2019 | 444 | Stipulation (5) Docket Text: STIPULATION and Proposed Order Staying the Case as to Defendant Alkem Laboratories, Ltd. by Alkem Laboratories Ltd.. (Dorsney, Kenneth) |
| Mar 13, 2019 | 441 | Letter (1) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Plaintiffs' Technology Tutorial. (Silver, Daniel) |
| Mar 13, 2019 | 442 | Notice of Service (7) Docket Text: NOTICE OF SERVICE of Plaintiff's Technology Tutorial filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Mar 13, 2019 | 443 | Letter (1) Docket Text: Letter to the Honorable Leonard P. Stark from Stamatios Stamoulis regarding Transmitting Defendants' Technology Tutorial. (Stamoulis, Stamatios) |
| Mar 12, 2019 | 435 | Notice to Take Deposition (4) Docket Text: NOTICE to Take Deposition of Arvashni Seeripat on March 14, 2019 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Mar 12, 2019 | 436 | Notice to Take Deposition (4) Docket Text: NOTICE to Take Deposition of William J. Jusko, Ph.D. on March 22, 2019 filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Mar 12, 2019 | 437 | Notice to Take Deposition (4) Docket Text: NOTICE to Take Deposition of Lawrence Steinman, M.D. on March 26, 2019 filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Mar 12, 2019 | 438 | Notice to Take Deposition (4) Docket Text: NOTICE to Take Deposition of Fred D. Lublin, M.D. on March 15, 2019 filed by Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Mar 12, 2019 | 439 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc.'s and Cadila Healthcare Limited's Objections and Responses to Novartis's Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Mar 12, 2019 | 440 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Objections and Responses to Plaintiffs Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Mar 11, 2019 | 434 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Objections and Responses to Novartis' Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Mar 8, 2019 | 432 | Notice of Service (7) Docket Text: NOTICE OF SERVICE of (1) Plaintiffs First Objections and Responses to Defendant Mylan Pharmaceuticals Inc.s First Set of Interrogatories to Plaintiff (Nos. 1-3); and (2) Novartiss Objections and Responses to Mylan Pharmaceuticals Inc.s Document Requests 1-4 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Mar 8, 2019 | 433 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Objections and Responses to Plaintiff's Notice of Deposition Under Fed. R. Civ. P. 30(b)(6) filed by Mylan Pharmaceuticals, Inc..(Ewing, Alexandra) |
| Mar 7, 2019 | 431 | Stipulation to EXTEND Time (3) Docket Text: STIPULATION TO EXTEND TIME to Submit Tutorials Describing the Technology and Matters in Issue to March 13, 2019 - filed by Mylan Pharmaceuticals, Inc.. (Rawnsley, Jason) |
| Mar 6, 2019 | 423 | Letter (2) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Response to Mylan's and Aurobindo's Letters - re [420] Letter, [421] Letter. (Silver, Daniel) |
| Mar 6, 2019 | 424 | Letter (2) Docket Text: Letter to The Honorable Leonard P. Stark from Eve H. Ormerod regarding Plaintiff's Request for Discovery Dispute Teleconference - re [419] Letter. (Ormerod, Eve) |
| Mar 6, 2019 | 425 | Motion for Leave to Appear Pro Hac Vice (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney James P. Barabas - filed by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Ormerod, Eve) |
| Mar 5, 2019 | 419 | Letter (2) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Requesting Discovery Dispute Conference. (Silver, Daniel) |
| Mar 5, 2019 | 420 | Letter (1) Docket Text: Letter to The Honorable Leonard P. Stark from Frederick L. Cottrell, III regarding Plaintiff's Request for Discovery Dispute Teleconference - re [419] Letter. (Cottrell, Frederick) |
| Mar 5, 2019 | 421 | Letter (2) Docket Text: Letter to The Honorable Leonard P. Stark from Kenneth L. Dorsney regarding Discovery Dispute - re [419] Letter. (Dorsney, Kenneth) |
| Mar 5, 2019 | 422 | Notice to Take Deposition (4) Docket Text: NOTICE to Take Deposition of Christopher A. Vellturo, Ph.D. on March 8, 2019 filed by Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Mar 4, 2019 | 410 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Alkem's Objections and Resposes to Plaintiff's Second Set of Common Interrogatories (No. 8) filed by Alkem Laboratories Ltd..(Dorsney, Kenneth) |
| Mar 4, 2019 | 411 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Defendant Accord Healthcare, Inc.'s Responses and Objections to Plaintiff's Second Set of Set of Common Interrogatories to All Defendants [No. 8]; (2) Defendants Dr. Reddy's Laboratories, Ltd., Dr. Reddys Laboratories, Inc.'s Responses and Objections to Plaintiff's Second Set of Set of Common Interrogatories to All Defendants [No. 8]; and (3) Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Responses and Objections to Plaintiff's Second Set of Set of Common Interrogatories to All Defendants [No. 8] filed by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Mar 4, 2019 | 412 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants' Teva Pharmaceuticals USA, Inc.'s and Actavis Elizabeth LLC's Objections and Responses to Plaintiff's Second Set of Common Interrogatories to All Defendants [No. 8] filed by Actavis Elizabeth LLC, Teva Pharmaceuticals USA Inc..(Keller, Karen) |
| Mar 4, 2019 | 413 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Plaintiff's Second Set of Common Interrogatories to All Defendants filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Mar 4, 2019 | 414 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Hetero's Responses to Second Set of Common Interrogatories (No. 8) and Prinston's Responses to Second Set of Common Interrogatories (No. 8) filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc..(Dorsney, Kenneth) |
| Mar 4, 2019 | 415 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Aurobindo's Response to Plaintiff's Second Set of Common Interrogatories (No. 8) filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
| Mar 4, 2019 | 416 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.'s Objections and Responses to Plaintiff's Second Set of Common Interrogatories to All Defendants [No. 8] filed by Mylan Pharmaceuticals, Inc..(Ewing, Alexandra) |
| Mar 4, 2019 | 417 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Objections and Responses to Plaintiff's Second Set of Common Interrogatories to All Defendants (No. 8) filed by Breckenridge Pharmaceutical, Inc., Standard Chemical & Pharmaceutical Co., Ltd..(Farnan, Kelly) |
| Mar 4, 2019 | 418 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Responses to Plaintiffs Second Set of Common Interrogatories to All Defendants [No. 8] filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Mar 1, 2019 | 408 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Aurobindo's Third Supplemental Responses to Plaintiff's First Set of Common Interrogatories (Nos. 1-7) filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
| Mar 1, 2019 | 409 | Motion for Leave to Appear Pro Hac Vice (4) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Michael R. Laing - filed by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
| Feb 28, 2019 | 405 | Redacted Document (30) Docket Text: REDACTED VERSION of [363] Declaration of Christopher A. Vellturo, Ph.D. by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Feb 28, 2019 | 406 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Second Supplemental Objections and Responses to Plaintiff's First Set of Common Interrogatories to All Defendants filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Feb 28, 2019 | 407 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Hetero's Document Production [HETERO.GILENYA-0063267-0070908] filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Dorsney, Kenneth) |
| Feb 26, 2019 | 396 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Third Supplemental Responses and Objections to Plaintiff's First Set of Common Interrogatories [Nos. 1-7] filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Feb 26, 2019 | 397 | Redacted Document (30) Docket Text: REDACTED VERSION of [358] Opening Brief in Support of Novartis' Motion for a Preliminary Injunction by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Feb 26, 2019 | 398 | Redacted Document (30) Docket Text: REDACTED VERSION of [359] Declaration of Lawrence Steinman, M.D. by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Feb 26, 2019 | 399 | Redacted Document (30) Docket Text: REDACTED VERSION of [360] Declaration of Fred D. Lublin, M.D. by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Feb 26, 2019 | 400 | Redacted Document (30) Docket Text: REDACTED VERSION of [361] Declaration of William J. Jusko, Ph.D by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Feb 26, 2019 | 401 | Redacted Document (22) Docket Text: REDACTED VERSION of [362] Declaration of Arvashni Seeripat by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Feb 26, 2019 | 402 | Main Document (28) Docket Text: REDACTED VERSION of [364] Declaration, of Robert W. Trenchard by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibits 1 - 17, # (2) Exhibits 18 - 25, # (3) Exhibits 26 - 47, # (4) Exhibits 48 - 56)(Silver, Daniel) |
| Feb 26, 2019 | 402 | Exhibits 1 - 17 (372) |
| Feb 26, 2019 | 402 | Exhibits 18 - 25 (309) |
| Feb 26, 2019 | 402 | Exhibits 26 - 47 (210) |
| Feb 26, 2019 | 402 | Exhibits 48 - 56 (182) |
| Feb 26, 2019 | 403 | Main Document (237) Docket Text: REDACTED VERSION of [366] Exhibit to a Document, [365] Exhibit to a Document, [367] Exhibit to a Document, Exhibits 57 - 139 to the Declaration of Rober W. Trenchard by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibits 81 - 108, # (2) EXhibits 109 - 115, # (3) Exhibits 116 - 139)(Silver, Daniel) |
| Feb 26, 2019 | 403 | Exhibits 81 - 108 (415) |
| Feb 26, 2019 | 403 | EXhibits 109 - 115 (3) |
| Feb 26, 2019 | 403 | Exhibits 116 - 139 (1) |
| Feb 26, 2019 | 404 | Main Document (395) Docket Text: REDACTED VERSION of [371] Exhibit to a Document, [367] Exhibit to a Document, [369] Exhibit to a Document, [368] Exhibit to a Document, [370] Exhibit to a Document, Exhibits 140 - 239 of Declaration of Robert W. Trenchard by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibits 144 - 146, # (2) Exhibits 147 - 152, # (3) Exhibits 153 - 160, # (4) Exhibits 161 - 173, # (5) Exhibits 174 - 239)(Silver, Daniel) |
| Feb 26, 2019 | 404 | Exhibits 144 - 146 (113) |
| Feb 26, 2019 | 404 | Exhibits 147 - 152 (98) |
| Feb 26, 2019 | 404 | Exhibits 153 - 160 (216) |
| Feb 26, 2019 | 404 | Exhibits 161 - 173 (227) |
| Feb 26, 2019 | 404 | Exhibits 174 - 239 (1) |
| Feb 25, 2019 | 394 | Main Document (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Laura Corbin - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Certification for Laura Corbin)(Silver, Daniel) |
| Feb 25, 2019 | 394 | Certification for Laura Corbin (1) |
| Feb 25, 2019 | 395 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Hetero's Third Amended Paragraph 3 Disclosures filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Dorsney, Kenneth) |
| Feb 22, 2019 | 393 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants Dr. Reddy's Laboratories, Inc. and Dr. Reddys Laboratories, Ltd.'s Third Supplemental Responses and Objections to Plaintiff's First Set of Common Interrogatories [Nos. 1-7] and Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Second Supplemental Responses and Objections to Plaintiff's First Set of Common Interrogatories [Nos. 1-7] filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Feb 21, 2019 | 391 | Main Document (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Jordan Bekier - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Certification for Jordan Bekier)(Silver, Daniel) |
| Feb 21, 2019 | 391 | Certification for Jordan Bekier (1) |
| Feb 21, 2019 | 392 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants' Supplemental Identification of Invalidity References Regarding U.S. Patent No. 9,187,405 filed by Mylan Pharmaceuticals, Inc..(Ewing, Alexandra) |
| Feb 20, 2019 | 381 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Hetero's Third Amended Response to Plaintiff's First Set of Common Interrogatories filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc..(Dorsney, Kenneth) |
| Feb 20, 2019 | 382 | Letter (1) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Discovery Teleconference Request for Novartis and HEC. (Silver, Daniel) |
| Feb 20, 2019 | 383 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Alpesh Pathak on March 12, 2019 at 9:30 am filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Feb 20, 2019 | 384 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of David Mitchell on March 15, 2019 at 9:30 a.m. filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Feb 20, 2019 | 385 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Amit Ghare on March 12, 2019 at 9:30 am filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Feb 20, 2019 | 386 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Radhika Dasari on March 15, 2019 at 9:30 a.m. filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Feb 20, 2019 | 387 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Arunesh Varma on March 13, 2019 at 9:30 a.m. filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Feb 20, 2019 | 388 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Elizabeth Purcell on March 14, 2019 at 9:30 a.m. filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Feb 20, 2019 | 389 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Anuj Srivastava on March 14, 2019 at 9:30 a.m. filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Feb 20, 2019 | 390 | Notice to Take Deposition (2) Docket Text: NOTICE to Take Deposition of Seshu Akula on March 13, 2019 at 9:30 a.m. filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Feb 19, 2019 | 356 | Redacted Document (30) Docket Text: REDACTED VERSION of [349] Letter to The Honorable Leonard P. Stark from Kenneth L. Dorsney regarding Hetero's Responsive Dispute Letter by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.. (Dorsney, Kenneth) |
| Feb 19, 2019 | 357 | Main Document (2) Docket Text: MOTION for Preliminary Injunction - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Proposed Order)(Silver, Daniel) |
| Feb 19, 2019 | 357 | Proposed Order (2) |
| Feb 19, 2019 | 372 | Notice (Other) (6) Docket Text: NOTICE of Deposition Under Federal Rule of Civil Procedure 30(b)(6) to Accord Healthcare Inc. by Novartis Pharmaceuticals Corporation (Silver, Daniel) |
| Feb 19, 2019 | 373 | Notice (Other) (6) Docket Text: NOTICE of Deposition Under Federal Rule of Civil Procedure 30(b)(6) to Alkem Laboratories, Ltd. by Novartis Pharmaceuticals Corporation (Silver, Daniel) |
| Feb 19, 2019 | 374 | Notice (Other) (6) Docket Text: NOTICE of Deposition Under Federal Rule of Civil Procedure 30(b)(6) to Aurobindo Pharma Limited and Aurobindo Pharma USA, Inc. by Novartis Pharmaceuticals Corporation (Silver, Daniel) |
| Feb 19, 2019 | 375 | Notice (Other) (6) Docket Text: NOTICE of Deposition Under Federal Rule of Civil Procedure 30(b)(6) to Dr. Reddy's Laboroatries, Inc. and Dr. Reddy's Laboratories, Ltd. by Novartis Pharmaceuticals Corporation (Silver, Daniel) |
| Feb 19, 2019 | 376 | Notice (Other) (6) Docket Text: NOTICE of Deposition Under Federal Rule of Civil Procedure 30(b)(6) to HEC Pharm Co., Ltd and HEC Pharm USA Inc. by Novartis Pharmaceuticals Corporation (Silver, Daniel) |
| Feb 19, 2019 | 377 | Notice (Other) (6) Docket Text: NOTICE of Deposition Under Federal Rule of Civil Procedure 30(b)(6) to Hetero Labs Limited, Hetero Labs Limited Unit-V, and Hetero USA Inc. by Novartis Pharmaceuticals Corporation (Silver, Daniel) |
| Feb 19, 2019 | 378 | Notice (Other) (6) Docket Text: NOTICE of Deposition Under Federal Rule of Civil Procedure 30(b)(6) to Mylan Pharmaceuticals, Inc. by Novartis Pharmaceuticals Corporation (Silver, Daniel) |
| Feb 19, 2019 | 379 | Notice (Other) (6) Docket Text: NOTICE of Deposition Under Federal Rule of Civil Procedure 30(b)(6) to Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited by Novartis Pharmaceuticals Corporation (Silver, Daniel) |
| Feb 19, 2019 | 380 | Notice (Other) (6) Docket Text: NOTICE of Deposition Under Federal Rule of Civil Procedure 30(b)(6) to Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd. by Novartis Pharmaceuticals Corporation (Silver, Daniel) |
| Feb 15, 2019 | 355 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Third Supplemental Response to Plaintiffs First Set of Common Interrogatories filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Feb 14, 2019 | 354 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants' First Supplemental Consolidated Invalidity Contentions Regarding U.S. Patent No. 9,187,405 filed by Mylan Pharmaceuticals, Inc..(Ewing, Alexandra) |
| Feb 13, 2019 | N/A | Order Cancelling Deadline (0) Docket Text: ORAL ORDER: Having reviewed the parties' letters and related materials (see, e.g., D.I. 347, 349), IT IS HEREBY ORDERED that: (i) Plaintiff's request that Hetero be barred from launching at-risk pending final resolution of this matter is DENIED, as the requested relief is "extremely unwarranted" (as Hetero correctly states) and would not be a reasonable consequence for Hetero's failures with respect to document production; (ii) Hetero SHALL complete its full document production as soon as possible and no later than February 28; (iii) Plaintiffs request that Hetero pay Novartis' fees in having to bring its motion is DENIED, although Hetero should understand that if it repeats its failure to meet deadlines and repeats its failure to give Plaintiff advance notice then the Court will impose a reasonable sanction; and (iv) Hetero SHALL, no later than February 20, respond to Interrogatory No. 3 by identifying the "key people involved in the decision about whether and when to launch the ANDA product," as disclosure of these identities is consistent with the Court's prior ruling (see D.I. 308 at 38-39) - although Hetero need not "provide a complete narrative response" that discloses "specific launch plans, specific dates, or other information about the launch plans." IT IS FURTHER ORDERED that the teleconference scheduled for today to discuss these disputes is CANCELLED. ORDERED by Judge Leonard P. Stark on 2/13/19. (ntl) |
| Feb 13, 2019 | 353 | Stipulation (5) Docket Text: STIPULATION Staying Claims Against Bionpharma Inc. by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Feb 12, 2019 | 351 | Stipulation (4) Docket Text: STIPULATION and Proposed Order Staying the Case as to Ezra by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Feb 7, 2019 | 347 | Letter (3) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Discovery Dispute - re [343] Order Setting Teleconference,,,,. (Silver, Daniel) |
| Feb 7, 2019 | 348 | Main Document (4) Docket Text: DECLARATION re [347] Letter of Paul Torchia by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit 1-3)(Silver, Daniel) |
| Feb 7, 2019 | 348 | Exhibit 1-3 (45) |
| Feb 6, 2019 | 345 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Third Supplemental Objections and Responses to Plaintiff's First Set of Common Interrogatories (Nos. 1-7) and Third Supplemental Objections and Responses to Plaintiff's First Set of Common Requests for Production (Nos. 1-30) filed by Mylan Pharmaceuticals, Inc..(Ewing, Alexandra) |
| Feb 6, 2019 | 346 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.'s: First Set of Interrogatories to Plaintiff Novartis Pharmaceuticals Corp. (Nos. 1-3) and First Set of Requests for the Production of Documents and Things (Nos. 1-4) filed by Mylan Pharmaceuticals, Inc..(Ewing, Alexandra) |
| Feb 5, 2019 | N/A | Order Setting Teleconference (0) Docket Text: ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter, IT IS HEREBY ORDERED that a teleconference is scheduled for February 13, 2019 at 11:00 a.m. Counsel for the party seeking relief shall initiate the teleconference call to 302-573-4571. IT IS FURTHER ORDERED that not later than February 7, 2019, any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than February 8, 2019, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Each party shall submit to the Court two (2) courtesy copies of its discovery letter and any attachments. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Leonard P. Stark on 2/5/19. (ntl) |
| Feb 5, 2019 | 344 | Stipulation (5) Docket Text: STIPULATION and Proposed Order Staying Claims Against Glenmark by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Feb 4, 2019 | 340 | Letter (1) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esquire regarding Scheduling of a Discovery Teleconference. (Silver, Daniel) |
| Feb 4, 2019 | 341 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME for Breckenridge to substantially complete its document production to February 15, 2019 - filed by Breckenridge Pharmaceutical, Inc., Standard Chemical & Pharmaceutical Co., Ltd.. (Farnan, Kelly) |
| Feb 4, 2019 | 342 | Notice of Service (8) Docket Text: NOTICE OF SERVICE of Plaintiff's Objections and Responses to Defendants' Second Joint Interrogatories to Plaintiff (Nos. 14-19) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Feb 1, 2019 | 338 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Aurobindo's Second Supplemental Responses and Objections to Plaintiff's First Set of Common Interrogatories filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
| Feb 1, 2019 | 339 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME for Plaintiff to Respond to Mylan's Motion to Seal Limited Sections of Transcript to through and including 14 days following the Court's ruling on the pending redaction dispute between Plaintiff and Mylan - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jan 31, 2019 | 337 | Notice of Service (8) Docket Text: NOTICE OF SERVICE of Plaintiff's Second Set of Common Interrogatories to All Defendants filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Jan 30, 2019 | 336 | Stipulation (4) Docket Text: STIPULATION and Proposed Order Extending Discovery and Precluding Prinston Pharmaceutical, Inc. from Launching at Risk by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jan 29, 2019 | 335 | Notice of Service (8) Docket Text: NOTICE OF SERVICE of Plaintiffs First Supplemental Objections and Responses to Defendants First Joint Interrogatories to Plaintiff (Nos. 1-13) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Jan 28, 2019 | 331 | Redacted Document (4) Docket Text: REDACTED VERSION of [296] Letter by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
| Jan 28, 2019 | 334 | Stipulation to EXTEND Time (4) Docket Text: STIPULATION TO EXTEND TIME for Biopharma to Substantially Complete its Document Production to February 15, 2019 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jan 25, 2019 | 328 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Defendant Mylan Pharmaceuticals Inc.'s Second Supplemental Objections and Responses to Plaintiff's First Set of Common Interrogatories (Nos. 1-7) and (2) Defendant Mylan Pharmaceuticals Inc.'s Second Supplemental Objections and Responses to Plaintiff's First Set of Common Requests for Production (Nos. 1-30) filed by Mylan Pharmaceuticals, Inc..(Ewing, Alexandra) |
| Jan 25, 2019 | 329 | Notice Requesting Removal of Co-Counsel (1) Docket Text: NOTICE requesting Clerk to remove Sarah K. Tsou as co-counsel.. (Hoeschen, Nathan) |
| Jan 25, 2019 | 330 | Letter (8) Docket Text: Joint Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Interim Status Report - re [216] Scheduling Order,,. (Silver, Daniel) |
| Jan 24, 2019 | 326 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants Zydus Pharmaceuticals (USA) Inc. and Cadila Helathcare Limited's First Supplemental Objections and Responses to Plaintiff's First Set of Common Interrogatories to All Defendants filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Jan 24, 2019 | 327 | Notice of Change of Address (2) Docket Text: NOTICE of Change of Address by Stamatios Stamoulis (Stamoulis, Stamatios) |
| Jan 18, 2019 | 325 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Aurobindo's Supplemental Paragraph 3 Disclosures; (2) Aurobindo's Supplemental Responses to First Set of Common Interrogatories; and (3) Aurobindo's Supplemental Response to First Set of Common Requests for Production filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
| Jan 17, 2019 | 324 | Main Document (3) Docket Text: Letter to the Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Preliminary Injunction Briefing and Related Issues - re [216] Scheduling Order,,. (Attachments: # (1) Proposed Order)(Silver, Daniel) |
| Jan 17, 2019 | 324 | Proposed Order (3) |
| Jan 15, 2019 | 318 | Stipulation (4) Docket Text: STIPULATION and Proposed Order Staying the Case as to Biocon by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jan 15, 2019 | 319 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Third Supplemental Responses to First Set of Common Interrogatories and (2) Second Supplemental Responses to First Set of Common Requests for Production filed by Alkem Laboratories Ltd..(Dorsney, Kenneth) |
| Jan 15, 2019 | 320 | Stipulation (4) Docket Text: STIPULATION and Proposed Order Extending Discovery and Precluding Breckenridge from Launching at Risk by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jan 15, 2019 | 321 | Stipulation to EXTEND Time (5) Docket Text: STIPULATION TO EXTEND TIME the Deadline for the Parties to Submit a Proposal for the Length of Briefing and the Format of a Preliminary Injunction Hearing to Thursday, January 17, 2019 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jan 15, 2019 | 322 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Second Supplemental Discovery Disclosures Pursuant to the District of Delaware's Default Standard for Discovery filed by Mylan Pharmaceuticals, Inc..(Ewing, Alexandra) |
| Jan 15, 2019 | 323 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendants HEC Pharm Co., Ltd. and HEC Pharm USA Inc.s Second Supplemental Response to Plaintiffs First Set of Common Interrogatories 1, 3-7, HEC Pharm Co., Ltd. and HEC Pharm USA Inc.s Fed. R. CIv. P. 26(a)(1) Initial Disclosures (Amended), and Defendants HEC Pharm Group and HEC Pharm USA, Inc.s Second Supplemental Response to Plaintiffs First Set of Common Requests for the Production of Documents and Things 1-30 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Jan 14, 2019 | 316 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's First Supplemental Objections and Responses to Plaintiff's First Set of Common Requests for the Production of Documents and Things filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Jan 14, 2019 | 317 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME for Teva to Substantially Complete Document Production to February 5, 2019 - filed by Teva Pharmaceuticals USA Inc.. (Keller, Karen) |
| Jan 11, 2019 | 312 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Defendant Accord Healthcare, Inc.'s Second Supplemental Responses and Objections to Plaintiff's First Set of Common Requests for the Production of Documents and Things [Nos. 1-30] (No. 25); (2) Defendants Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc.'s Second Supplemental Responses and Objections to Plaintiff's First Set of Common Requests for the Production of Documents and Things [Nos. 1-30] (No. 25); and (3) Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Second Supplemental Responses and Objections to Plaintiff's First Set of Common Requests for the Production of Documents and Things [Nos. 1-30] (No. 25) filed by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Jan 11, 2019 | 313 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Defendants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.'s Second Supplemental Responses and Objections to Plaintiff's First Set of Common Interrogatories (Nos. 1-7) filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Ormerod, Eve) |
| Jan 11, 2019 | 314 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Amended Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery, Including Discovery of Electronically Stored Information filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Jan 11, 2019 | 315 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Amended Initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Jan 10, 2019 | 310 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Defendants Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc.'s Amended Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery, Including Discovery of Electronically Stored Information filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Ormerod, Eve) |
| Jan 10, 2019 | 311 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1). BIONPHARMAS SECOND AMENDED INITIAL PARAGRAPH 3 DISCLOSURES; (2). BIONPHARMAS SECOND AMENDED RESPONSES TO FIRST SET OF REQUESTS FOR PRODUCTION (NOS. 1-30); (3). BIONPHARMAS SECOND AMENDED RESPONSES TO FIRST SET OF INTERROGATORIES (NOS. 1-7); (4) HETEROS SECOND AMENDED INITIAL PARAGRAPH 3 DISCLOSURES; (5) HETEROS SECOND AMENDED RESPONSES TO FIRST SET OF REQUESTS FOR PRODUCTION (NOS. 1-30); (6) HETEROS SECOND AMENDED RESPONSES TO FIRST SET OF INTERROGATORIES (NOS. 1-7); (7) PRINSTONS SECOND AMENDED INITIAL PARAGRAPH 3 DISCLOSURES; (8) PRINSTONS SECOND AMENDED RESPONSES TO FIRST SET OF REQUESTS FOR PRODUCTION (NOS. 1-30); AND (9). PRINSTONS SECOND AMENDED RESPONSES TO FIRST SET OF INTERROGATORIES (NOS. 1-7) filed by Bionpharma Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc..(Dorsney, Kenneth) |
| Jan 9, 2019 | 309 | Stipulation (5) Docket Text: STIPULATION and Proposed Order Extending Discovery and Precluding Glenmark from Launching at Risk by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Jan 7, 2019 | 307 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Defendant Accord Healthcare Inc.'s (1) Second Supplemental Responses and Objections to Plaintiff's First Set of Common Interrogatories (Nos. 3 and 7); and (2) Amended Delaware Paragraph 3 Disclosures filed by Accord Healthcare Inc..(Ormerod, Eve) |
| Jan 4, 2019 | 306 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants' Second Joint Interrogatories to Plaintiff (Nos. 14-19) filed by Actavis Elizabeth LLC, Teva Pharmaceuticals USA Inc..(Hoeschen, Nathan) |
| Dec 28, 2018 | 305 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of 1) Defendants' Second Supplemental Initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery; 2) Defendants' Supplemental Objections and Responses to Plaintiff's First Set of Common Requests for Production (Nos. 7-16, 18, 20, 22-25); and 3) Defendants' Supplemental Responses and Objections to Plaintiff's First Set of Interrogatories (Nos. 1, 3-7) filed by Actavis Elizabeth LLC, Teva Pharmaceuticals USA Inc..(Hoeschen, Nathan) |
| Dec 21, 2018 | N/A | Discovery Conference (0) Docket Text: Minute Entry for proceedings held before Judge Leonard P. Stark - Discovery Teleconference held on 12/21/2018. (Court Reporter B. Gaffigan.) (ntl) |
| Dec 21, 2018 | 304 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Second Supplemental Response to First Set of Common Interrogatories filed by Alkem Laboratories Ltd..(Dorsney, Kenneth) |
| Dec 20, 2018 | 303 | Notice of Service (9) Docket Text: NOTICE OF SERVICE of Novartiss Objections and Responses to Defendants Third Joint Requests for Production to Plaintiff (Nos. 65-76) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Dec 19, 2018 | 302 | Stipulation (5) Docket Text: STIPULATION and Proposed Order Staying the Case as to Heritage and Emcure by Emcure Pharmaceuticals, Heritage Pharmaceuticals Inc.. (Haney, Megan) |
| Dec 18, 2018 | 300 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Defendant Accord Healthcare, Inc.'s Supplemental Responses and Objections to Plaintiff's First Set of Common Requests for the Production of Documents and Things [Nos. 1-30]; (2) Defendants Dr. Reddy's Laboratories, Ltd., Dr. Reddy's Laboratories, Inc.'s Supplemental Responses and Objections to Plaintiff's First Set of Common Requests for the Production of Documents and Things [Nos. 1-30]; and (3) Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Supplemental Responses and Objections to Plaintiff's First Set of Common Requests for the Production of Documents and Things [Nos. 1-30] filed by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Dec 18, 2018 | 301 | Main Document (3) Docket Text: Letter to The Honorable Leonard P. Stark from Eve H. Ormerod regarding Responsive Position with respect to Discovery Dispute - re [289] Order,,,,. (Attachments: # (1) Exhibits 1-11)(Ormerod, Eve) |
| Dec 18, 2018 | 301 | Exhibits 1-11 (236) |
| Dec 17, 2018 | 299 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendant Alkem's First Supplemental Objections and Responses to Plaintiff's First Set of Common Requests for Production filed by Alkem Laboratories Ltd..(Dorsney, Kenneth) |
| Dec 14, 2018 | 294 | Letter (4) Docket Text: Letter to The Honorable Leonard P. Stark from Kenneth L. Dorsney regarding Aurobindo's responsive discovery dispute letter. (Dorsney, Kenneth) |
| Dec 14, 2018 | 295 | Declaration (6) Docket Text: DECLARATION re [294] Letter -- executed by George J. Barry III -- by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc.. (Dorsney, Kenneth) |
| Dec 14, 2018 | 297 | Letter (21) Docket Text: Letter to The Honorable Leonard P. Stark from Kenneth L. Dorsney regarding Discovery Dispute - re [287] Letter. (Dorsney, Kenneth) |
| Dec 14, 2018 | 298 | Main Document (4) Docket Text: Letter to The Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Zydus's Response to Plaintiff's December 12, 2018 Letter - re [287] Letter. (Attachments: # (1) Exhibit 1)(Phillips, John) |
| Dec 14, 2018 | 298 | Exhibit 1 (5) |
| Dec 13, 2018 | 290 | Letter (2) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Plaintiffs Dispute with Accord, Dr. Reddy's, and Torrent - re [289] Order,,,,. (Silver, Daniel) |
| Dec 13, 2018 | 291 | Main Document (3) Docket Text: DECLARATION re [290] Letter of Paul Torchia by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit 1-8)(Silver, Daniel) |
| Dec 13, 2018 | 291 | Exhibit 1-8 (198) |
| Dec 13, 2018 | 292 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Defendant Accord Healthcare Inc.'s Second Supplemental Responses and Objections to Plaintiff's First Set of Common Interrogatories (Nos. 1-7) filed by Accord Healthcare Inc..(Ormerod, Eve) |
| Dec 13, 2018 | 293 | Notice of Service (4) Docket Text: NOTICE OF SERVICE of Defendants Consolidated Invalidity Contentions Regarding U.S. Patent No. 9,187,405 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Dec 12, 2018 | 287 | Letter (6) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Plaintiffs Disputes with Zydus, Aurobindo, Hetero, Bionpharma and Prinston. (Silver, Daniel) |
| Dec 12, 2018 | 288 | Main Document (8) Docket Text: DECLARATION re [287] Letter of Paul Torchia by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit 1-17)(Silver, Daniel) |
| Dec 12, 2018 | 288 | Exhibit 1-17 (332) |
| Dec 10, 2018 | 271 | Letter (2) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Request the Scheduling of a Discovery Teleconference. (Silver, Daniel) |
| Dec 10, 2018 | N/A | Order Setting Teleconference (0) Docket Text: ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter (See D.I. 243, 265, 266, 267), IT IS HEREBY ORDERED that a teleconference is scheduled for December 21, 2018 at 1:00 p.m. Counsel for the party seeking relief shall initiate the teleconference call to 302-573-4571. IT IS FURTHER ORDERED that not later than December 12, 2018, any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than December 14, 2018, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Each party shall submit to the Court two (2) courtesy copies of its discovery letter and any attachments. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Leonard P. Stark on 12/10/18. (ntl) |
| Dec 10, 2018 | 273 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Alkem's responses to Plaintiff's First Set of Interrogatories (Nos. 1-3) filed by Alkem Laboratories Ltd..(Dorsney, Kenneth) |
| Dec 10, 2018 | 274 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Aurobindo's response to Plaintiff's First Set of Interrogatories (Nos. 1-3) filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
| Dec 10, 2018 | 275 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Bionpharma, Hetero and Prinston's responses to Plaintiff's First Set of Interrogatories (Nos. 1-3) filed by Bionpharma Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc..(Dorsney, Kenneth) |
| Dec 10, 2018 | 276 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants Glenmark Pharmaceuticals, Inc., USA and Glenmark Pharmaceuticals Limited's Objections and Responses to Plaintiff's First Set of Interrogatories Directed to Glenmark (Nos. 1- 3) filed by Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals Limited.(Poff, Adam) |
| Dec 10, 2018 | 277 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Plaintiff's First Set of Interrogatories (1-3) to Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Dec 10, 2018 | 278 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Defendants Biocon Limited and Biocon Pharma, Inc.'s Supplemental Objections and Responses to Plaintiff's First Set of Common Interrogatories 1-7; and (2) Defendants Biocon Limited and Biocon Pharma, Inc.'s Objections and Responses to Plaintiff's First Set of Interrogatories to Biocon (1-3) filed by Biocon Limited, Biocon Pharma, Inc..(Haney, Megan) |
| Dec 10, 2018 | 279 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants' Objections and Responses to Plaintiff's First Set of Interrogatories (Nos. 1-3) to Emcure Pharmaceuticals and Heritage Pharmaceuticals Inc. filed by Emcure Pharmaceuticals, Heritage Pharmaceuticals Inc..(Haney, Megan) |
| Dec 10, 2018 | 280 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Defendants' Responses and Objections to Plaintiffs' First Set of Interrogatories to Teva and Actavis (Nos. 1-3) filed by Teva Pharmaceuticals USA Inc..(Keller, Karen) |
| Dec 10, 2018 | 281 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Defendant Accord Healthcare, Inc.'s Responses and Objections to Plaintiff's First Set of Interrogatories (Nos. 1-3); (2) Defendants Dr. Reddy's Laboratories, Ltd., Dr. Reddy's Laboratories, Inc.'s Responses and Objections to Plaintiff's First Set of Interrogatories (Nos. 1-3); and (3) Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Responses and Objections to Plaintiff's First Set of Interrogatories (Nos. 1-3) filed by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Dec 10, 2018 | 282 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Objections and Responses to Plaintiffs First Set of Interrogatories Nos. 1-3 filed by Breckenridge Pharmaceutical, Inc., Standard Chemical & Pharmaceutical Co., Ltd..(Farnan, Kelly) |
| Dec 10, 2018 | 283 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.'s Objections and Responses to Plaintiff's First Set of Interrogatories to Mylan Pharmaceuticals Inc. [Nos. 1-3] filed by Mylan Pharmaceuticals, Inc..(Ewing, Alexandra) |
| Dec 10, 2018 | 284 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Responses to Plaintiffs First Set of Interrogatories (1-3) filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Dec 10, 2018 | 285 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Responses to Plaintiffs First Set of Interrogatories (1-3) filed by Ezra Ventures, LLC.(Stamoulis, Stamatios) |
| Dec 6, 2018 | 269 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.'s First Supplemental Objections and Responses to Plaintiff's First Set of Common Interrogatories to All Defendants (Nos. 1-7) filed by Mylan Pharmaceuticals, Inc..(Ewing, Alexandra) |
| Dec 6, 2018 | 270 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.'s First Supplemental Objections and Responses to Plaintiff's First Set of Common Requests for the Production of Documents and Things to All Defendants (Nos. 1-30) filed by Mylan Pharmaceuticals, Inc..(Ewing, Alexandra) |
| Dec 5, 2018 | 266 | Letter (2) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Scheduling a Discovery Conference. (Silver, Daniel) |
| Dec 5, 2018 | 267 | Letter (2) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Scheduling a Discovery Conference. (Silver, Daniel) |
| Dec 5, 2018 | 268 | Motion for Leave to Appear Pro Hac Vice (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Bryan D. Beel - filed by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
| Dec 4, 2018 | 265 | Letter (2) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Scheduling a Discovery Teleconference. (Silver, Daniel) |
| Dec 3, 2018 | 264 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendants HEC Pharm Co., Ltd. and HEC Pharm USA Inc.s First Supplemental Response to Plaintiffs First Set of Common Requests for the Production of Documents and Things 1-30 and Defendants HEC Pharm Co., Ltd and HEC Pharm USA Inc.s First Supplemental Response to Plaintiffs First Set of Common Interrogatories 1-7 filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Nov 30, 2018 | 263 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Alkem's First Supplemental Responses to First Set of Common Interrogatories (Nos. 1-6) filed by Alkem Laboratories Ltd..(Dorsney, Kenneth) |
| Nov 29, 2018 | 262 | Affidavit of Service (1) Docket Text: AFFIDAVIT of Service for Subpoena Duces Tecum served on Peter Arthur Calabresi, M.D. on November 26, 2018, filed by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Ormerod, Eve) |
| Nov 28, 2018 | 261 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Defendants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.'s Supplemental Responses and Objections to Plaintiff's First Set of Common Interrogatories (Nos. 1-7) and Defendant Accord Healthcare Inc.'s Supplemental Responses and Objections to Plaintiff's First Set of Common Interrogatories (Nos. 1-7) filed by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Ormerod, Eve) |
| Nov 26, 2018 | 260 | Notice of Service (9) Docket Text: NOTICE OF SERVICE of Novartiss Objections and Responses to Defendants Second Joint Requests for Production to Plaintiff (Nos. 60-64) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Nov 20, 2018 | 257 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Supplemental Responses and Objections to Plaintiff's First Set of Common Interrogatories (Nos. 1-7) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Nov 20, 2018 | 258 | Main Document (1) Docket Text: NOTICE OF SERVICE of Subpoena Duces Tecum to Peter Arthur Calabresi, M.D. filed by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Attachments: # (1) Exhibit 1 to Notice of Subpoena, # (2) Exhibit A to Subpoena)(Ormerod, Eve) |
| Nov 20, 2018 | 258 | Exhibit 1 to Notice of Subpoena (4) |
| Nov 20, 2018 | 258 | Exhibit A to Subpoena (4) |
| Nov 20, 2018 | 259 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Third Joint Requests for Production (Nos. 65-76) filed by Alkem Laboratories Ltd., Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc., Bionpharma Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc..(Dorsney, Kenneth) |
| Nov 19, 2018 | 256 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) Bionpharma, Hetero and Prinston's Amended Responses to Plaintiff's First Set of Common Interrogatories (No. 7); and (2) Bionpharma, Hetero and Prinston's Amended Responses to Plaintiff's First Set of Common Requests for Production (Nos. 8-10, 18) filed by Bionpharma Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc..(Dorsney, Kenneth) |
| Nov 16, 2018 | 253 | Letter (1) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Request for Relief - re [244] Letter. (Silver, Daniel) |
| Nov 16, 2018 | 254 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendants Bionpharma, Hetero and Prinston's Amended Paragraph 3 Disclosures filed by Bionpharma Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc..(Dorsney, Kenneth) |
| Nov 16, 2018 | 255 | Letter (2) Docket Text: Letter to the Honorable Leonard P. Stark from Stamatios Stamoulis regarding Regarding Order on Discovery Dispute Request - re [239] Order,. (Stamoulis, Stamatios) |
| Nov 14, 2018 | 248 | Redacted Document (11) Docket Text: REDACTED VERSION of [247] Letter to The Honorable Leonard P. Stark from Kenneth L. Dorsney responding to Plaintiff's Novenber 13, 2018 letter regarding meet and confer with Alkem by Alkem Laboratories Ltd.. (Dorsney, Kenneth) (Main Document 248 replaced on 11/14/2018) (ntl). |
| Nov 14, 2018 | 249 | Stipulation (5) Docket Text: STIPULATION and Proposed Order to Stay Between Plaintiff and Sun by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Nov 14, 2018 | 250 | Motion for Leave to Appear Pro Hac Vice (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Alan H. Pollack - filed by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Ormerod, Eve) |
| Nov 14, 2018 | 251 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Novartiss Objections and Responses to Accord, DRL, and Torrents Document Requests Nos. 1-3 filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Nov 14, 2018 | 252 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendant Ezra Ventures LLCs Amended Responses to Plaintiffs First Set of Common Requests for the Production of Documents and Things to All Defendants and Defendant Ezra Ventures LLCs Amended Responses to Plaintiffs First Set of Common Interrogatories to All Defendants filed by Ezra Ventures, LLC.(Stamoulis, Stamatios) |
| Nov 13, 2018 | 244 | Main Document (2) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Meet and Confer with Defedant Alkem Laboratories Ltd.. (Attachments: # (1) Exhibit 1)(Silver, Daniel) |
| Nov 13, 2018 | 244 | Exhibit 1 (5) |
| Nov 13, 2018 | 245 | Notice of Service (17) Docket Text: NOTICE OF SERVICE of Subpoenas filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Nov 13, 2018 | 246 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants Emcure Pharmaceuticals and Heritage Pharmaceuticals Inc.'s Supplemental Disclosures Pursuant to Delaware Default Standard for Discovery Paragraph 3 filed by Emcure Pharmaceuticals, Heritage Pharmaceuticals Inc..(Haney, Megan) |
| Nov 9, 2018 | 243 | Letter (1) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Discovery Dispute Teleconference. (Silver, Daniel) |
| Nov 8, 2018 | 241 | Notice of Service (17) Docket Text: NOTICE OF SERVICE of Plaintiffs First Set of Interrogatories (1-3) to Defendants filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Nov 8, 2018 | 242 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Supplemental Initial Disclosures of Defendants Biocon Limited and Biocon Pharma Inc. Pursuant to Paragraph 3 of the Default Standard for Discovery filed by Biocon Limited, Biocon Pharma, Inc..(Haney, Megan) |
| Nov 7, 2018 | 240 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Responses to Plaintiffs First Set of Requests for the Production of Documents and Things to Defendant Ezra Ventures LLC filed by Ezra Ventures, LLC.(Stamoulis, Stamatios) |
| Nov 6, 2018 | 238 | Main Document (3) Docket Text: OBJECTIONS by Novartis Pharmaceuticals Corporation OPPOSITION TO THE MOTION TO STAY AND FOR JOINDER IN APOTEXS MOTION TO STAY BY THE SUN DEFENDANTS (D.I. 33 IN C.A. NO. 18-1040-LPS). (Attachments: # (1) Exhibit A)(Silver, Daniel) |
| Nov 6, 2018 | 238 | Exhibit A (2) |
| Nov 5, 2018 | 234 | Main Document (2) Docket Text: Letter to the Honorable Leonard P. Stark from Stamatios Stamoulis regarding Requesting Discovery Dispute Conference. (Attachments: # (1) Exhibit A, # (2) Exhibit B)(Stamoulis, Stamatios) |
| Nov 5, 2018 | 234 | Exhibit A (10) |
| Nov 5, 2018 | 234 | Exhibit B (4) |
| Nov 5, 2018 | 235 | Stipulation of Dismissal (4) Docket Text: STIPULATION of Dismissal Against Defendants Nostrum Laboratories, Inc., Nostrum Pharmaceuticals, LLC, MSN Laboratories Private Limited, and MSN Pharmaceuticals Inc. by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Nov 5, 2018 | 236 | Letter (30) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Responsive Letter - re [234] Letter. (Silver, Daniel) |
| Nov 5, 2018 | 237 | Stipulation (5) Docket Text: STIPULATION -- Stipulation and Proposed Order to Stay Between Plaintiff and Apotex by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Nov 2, 2018 | 230 | Redacted Document (27) Docket Text: REDACTED VERSION of [220] Letter, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Nov 2, 2018 | 231 | Order Setting Mediation Conferences (5) Docket Text: ORDER Setting Mediation Conference: A Telephone Conference is set for 12/3/2018 at 11:00 AM before Judge Christopher J. Burke to discuss ADR. Signed by Judge Christopher J. Burke on 11/2/2018. (dlb) |
| Nov 2, 2018 | 232 | Redacted Document (4) Docket Text: REDACTED VERSION of [219] Letter, by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
| Nov 2, 2018 | 233 | Redacted Document (3) Docket Text: REDACTED VERSION of [224] Letter by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
| Nov 1, 2018 | 229 | Stipulation (3) Docket Text: STIPULATION Stipulated Amendment to Protective Order Between Novartis and Glenmark re [217] Protective Order by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Oct 31, 2018 | 226 | Notice of Service (18) Docket Text: NOTICE OF SERVICE of Plaintiff's Preliminary Infringement Contentions for Defendants filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Oct 31, 2018 | 227 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendant Actavis Elizabeth LLC'S Objections and Responses to Plaintiffs First Set of Requests for Production (No. 1) filed by Actavis Elizabeth LLC.(Hoeschen, Nathan) |
| Oct 31, 2018 | 228 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Responses to Plaintiffs First Set of Requests for the Production of Documents and Things to Defendants HEC Pharm Co., Ltd and HEC Pharm USA Inc. filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Oct 26, 2018 | 221 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants Breckenridge Pharmaceutical, Inc. and Standard Chemical & Pharmaceutical Co., Ltd.'s Supplemental Initial Disclosures filed by Breckenridge Pharmaceutical, Inc., Standard Chemical & Pharmaceutical Co., Ltd..(Farnan, Kelly) |
| Oct 26, 2018 | 222 | Redacted Document (11) Docket Text: REDACTED VERSION of [206] Reply Brief by Mylan Pharmaceuticals, Inc.. (Ewing, Alexandra) |
| Oct 26, 2018 | 223 | Main Document (3) Docket Text: REDACTED VERSION of [207] Declaration by Mylan Pharmaceuticals, Inc.. (Attachments: # (1) Exhibit 1-2)(Ewing, Alexandra) |
| Oct 26, 2018 | 223 | Exhibit 1-2 (9) |
| Oct 25, 2018 | N/A | Case Referred to Mediation (0) Docket Text: CASE REFERRED to Magistrate Judge Christopher J. Burke for Mediation. Please see Standing Order dated January 20, 2016, regarding disclosure of confidential ADR communications. A link to the standing order is provided here for your convenience at http://www.ded.uscourts.gov/general-orders/magistrate-judges-standing-order-adr-mediation (cak) |
| Oct 25, 2018 | N/A | Oral Order (0) Docket Text: ORAL ORDER: Having reviewed the parties' most recent submission relating to scheduling and the protective order (see C.A. No. 18-1038 D.I. 47), and considering the parties' earlier related submissions and the Court's discussion of the issues with the parties on October 16, the Court will today be docketing the scheduling order, protective order, and ESI order to govern these cases. The Court has exercised its discretion in the fashion it believes most reasonable to all involved, balancing important competing interests on each side. In particular, with respect to scheduling: the Court agrees with Novartis that there should be some time limit on Rule 30(b)(6) deposition hours but believes Novartis' proposed limit is too short; the Court agrees with Defendants' to allow lengthier depositions of inventors; and the Court agrees with Novartis to allow lengthier depositions of expert(s) who provide opinions on both infringement and validity. With respect to the protective order, the Court believes that good cause has been shown to preclude Plaintiffs' counsel who are in receipt of Defendants' protected information from participating in the drafting, crafting, or amending of any patent claims, and the Court believes its combination of provisions proposed by both sides has resulted in a mechanism for, when needed, the sharing and potential use of one Defendant's information against another Defendant, while providing adequate protections to all parties and not unduly risking burdening the Court. Ordered by Judge Leonard P. Stark on 10/25/2018. (etg) |
| Oct 25, 2018 | 216 | Scheduling Order (26) Docket Text: SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Fact Discovery completed by 6/4/2019. Status Report due by 1/25/2019. Claim Construction Opening Brief due by 2/28/2019. Claim Construction Answering Brief due by 4/2/2019. A Markman Hearing is set for 4/23/2019 at 02:00 PM in Courtroom 6B before Judge Leonard P. Stark. Proposed Pretrial Order due by 1/6/2020. A Pretrial Conference is set for 2/21/2020 at 04:00 PM in Courtroom 6B before Judge Leonard P. Stark. A Bench Trial is set for 3/2/2020 at 08:30 AM in Courtroom 6B before Judge Leonard P. Stark. Signed by Judge Leonard P. Stark on 10/25/2018. (etg) |
| Oct 25, 2018 | 217 | Protective Order (30) Docket Text: PROTECTIVE ORDER. Signed by Judge Leonard P. Stark on 10/25/2018. (etg) |
| Oct 25, 2018 | 218 | Order (15) Docket Text: ORDER FOR DISCOVERY, INCLUDING DISCOVERY OF ELECTRONICALLY STORED INFORMATION("ESI"). Signed by Judge Leonard P. Stark on 10/25/2018. (etg) |
| Oct 23, 2018 | 211 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.'s Supplemental Discovery Disclosures Pursuant to the District of Delaware's Default Standard for Discovery filed by Mylan Pharmaceuticals, Inc..(Cottrell, Frederick) |
| Oct 23, 2018 | 212 | Transcript (39) Docket Text: Official Transcript of Telephone Conference held on October 16, 2018 before Chief Judge Leonard P. Stark. Court Reporter Brian Gaffigan, Telephone (302) 573-6360. Transcript may be viewed at the court public terminal or purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 11/13/2018. Redacted Transcript Deadline set for 11/23/2018. Release of Transcript Restriction set for 1/22/2019.(bpg) |
| Oct 23, 2018 | 213 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendants' Second Set of Joint Requests for Production to Novartis (Nos. 60-64) filed by Bionpharma Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc..(Dorsney, Kenneth) |
| Oct 23, 2018 | 214 | Main Document (6) Docket Text: Joint Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Rule 16 Teleconference. (Attachments: # (1) Proposed Scheduling Order, # (2) Proposed Protective Order, # (3) Proposed ESI Order)(Silver, Daniel) |
| Oct 23, 2018 | 214 | Proposed Scheduling Order (26) |
| Oct 23, 2018 | 214 | Proposed Protective Order (33) |
| Oct 23, 2018 | 214 | Proposed ESI Order (15) |
| Oct 22, 2018 | 208 | Main Document (2) Docket Text: NOTICE OF SERVICE of Subpoenas and Discovery Requests filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Subpoena to Mylan Specialty L.P., # (2) Subpoena to Therese Guariano Fresconi)(Silver, Daniel) |
| Oct 22, 2018 | 208 | Subpoena to Mylan Specialty L.P. (14) |
| Oct 22, 2018 | 208 | Subpoena to Therese Guariano Fresconi (14) |
| Oct 22, 2018 | 210 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Supplemental Initial Disclosures Pursuant to Paragraph 3 of the Delware Default Standard for Discovery filed by Alkem Laboratories Ltd..(Dorsney, Kenneth) |
| Oct 17, 2018 | 205 | Notice of Service (15) Docket Text: NOTICE OF SERVICE of (1) Plaintiff's Objections and Responses to Defendants' First Joint Interrogatories to Plaintiff (Nos. 1-13) and (2) Novartis's Objections and Responses to Defendants' First Joint Requests for Production to Novartis (Nos. 1-59) filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Oct 16, 2018 | N/A | Scheduling Conference (0) Docket Text: Minute Entry for proceedings held before Judge Leonard P. Stark - Discovery/Scheduling teleconference held on 10/16/2018 (Court Reporter B. Gaffigan.) Associated Cases: 1:18-cv-01038-LPS, 1:18-cv-01039-LPS, 1:18-cv-01040-LPS, 1:18-cv-01043-LPS (ntl) |
| Oct 16, 2018 | 202 | Motion for Leave to Appear Pro Hac Vice (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Robert F. Vroom - filed by Breckenridge Pharmaceutical, Inc.. (Farnan, Kelly) |
| Oct 16, 2018 | 204 | Main Document (1) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Stephen P. Benson and Kimberly A. Beis - filed by Biocon Limited, Biocon Pharma, Inc.. (Attachments: # (1) Certification of Stephen P. Benson, # (2) Certification of Kimberly A. Beis)(Haney, Megan) |
| Oct 16, 2018 | 204 | Certification of Stephen P. Benson (1) |
| Oct 16, 2018 | 204 | Certification of Kimberly A. Beis (1) |
| Oct 15, 2018 | 200 | Main Document (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney David J. Austin - filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., Nostrum Laboratories Inc., Nostrum Pharmaceuticals, LLC. (Attachments: # (1) Certification of David J. Austin)(Finger, David) |
| Oct 15, 2018 | 200 | Certification of David J. Austin (1) |
| Oct 15, 2018 | 201 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Defendants Accord Healthcare, Inc., Dr. Reddy's Laboratories, Ltd., Dr. Reddy's Laboratories, Inc., Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s First Set of Requests for the Production of Documents and Things [Nos. 1-3] filed by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Oct 12, 2018 | 198 | Main Document (4) Docket Text: Letter to the Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Response to Defendants' October 11, 2016 Letter - re (39 in 1:18-cv-01038-LPS, 197 in 1:18-cv-01043-LPS, 26 in 1:18-cv-01040-LPS, 28 in 1:18-cv-01039-LPS) Letter. (Attachments: # (1) Exhibit E)(Silver, Daniel) |
| Oct 12, 2018 | 198 | Exhibit E (10) |
| Oct 12, 2018 | 199 | Main Document (5) Docket Text: Letter to The Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Defendants' Response to Plaintiff's Opening Discovery Dispute Letter - re (38 in 1:18-cv-01038-LPS, 196 in 1:18-cv-01043-LPS, 27 in 1:18-cv-01039-LPS, 25 in 1:18-cv-01040-LPS) Letter. (Attachments: # (1) Exhibit 1 - 4)(Phillips, John) |
| Oct 12, 2018 | 199 | Exhibit 1 - 4 (38) |
| Oct 11, 2018 | 193 | Notice of Appearance (1) Docket Text: NOTICE of Appearance by Alexandra M. Ewing on behalf of Mylan Pharmaceuticals, Inc. (Ewing, Alexandra) |
| Oct 11, 2018 | 194 | Letter (2) Docket Text: Letter to The Honorable Leonard P. Stark from Frederick L. Cottrell, III regarding Mylan Pharmaceuticals Inc.'s Response to Novartis' letter regarding Opposition to Mylan Pharmaceuticals Inc.'s Motion to Dismiss for Improper Venue - re [191] Letter. (Cottrell, Frederick) |
| Oct 11, 2018 | 195 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Defendants Biocon Limited and Biocon Pharma, Inc.'s Objections and Responses to Plaintiff's First Set of Common Interrogatories 1-7; and (2) Defendants Biocon Limited and Biocon Pharma, Inc.'s Objections and Responses to Plaintiff's First Set of Common Requests for the Production of Documents and Things 1-30 filed by Biocon Limited, Biocon Pharma, Inc..(Haney, Megan) |
| Oct 11, 2018 | 196 | Main Document (4) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Disputes About the Proposed Scheduling Order and Proposed ESI and Protective Orders. (Attachments: # (1) Exhibit A - D)(Silver, Daniel) |
| Oct 11, 2018 | 196 | Exhibit A - D (78) |
| Oct 11, 2018 | 197 | Letter (5) Docket Text: Letter to the Honorable Leonard P. Stark from John C. Phillips, Jr. regarding Defendants' Opening Dispute Letter. (Phillips, John) |
| Oct 10, 2018 | N/A | Oral Order (0) Docket Text: ORAL ORDER: IT IS HEREBY ORDERED that the Teleconference set for 10/16/18 at 02:00 PM is RESCHEDULED for 10/16/2018 at 2:45 PM before Judge Leonard P. Stark. Ordered by Judge Leonard P. Stark on 10/10/2018. (etg) |
| Oct 9, 2018 | 188 | Motion for Leave to Appear Pro Hac Vice (5) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Christie R.W. Matthaei - filed by Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals Limited. (Poff, Adam) |
| Oct 9, 2018 | 189 | Motion for Leave to Appear Pro Hac Vice (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Charles A. Weiss - filed by Bionpharma Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc.. (Dorsney, Kenneth) |
| Oct 9, 2018 | N/A | Oral Order (0) Docket Text: ORAL ORDER: After having been advised by Plaintiff(s) and Defendant(s) of their inability to resolve a discovery matter, IT IS HEREBY ORDERED that a discovery and scheduling teleconference is scheduled for October 16, 2018 at 2:00 p.m. Counsel for the party seeking relief shall initiate the teleconference call to 302-573-4571. IT IS FURTHER ORDERED that not later than October 11, 2018, any party seeking relief shall file with the Court a letter, not to exceed three (3) pages, outlining the issues in dispute and its position on those issues. Not later than October 12, 2018, any party opposing the application for relief may file a letter, not to exceed three (3) pages, outlining that party's reasons for its opposition. Each party shall submit to the Court two (2) courtesy copies of its discovery letter and any attachments. Should the Court find further briefing necessary upon conclusion of the telephone conference, the Court will order it. Alternatively, the Court may choose to resolve the dispute prior to the telephone conference and will, in that event, cancel the conference. ORDERED by Judge Leonard P. Stark on 10/9/2018. (etg) |
| Oct 9, 2018 | 191 | Letter (1) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Novartis Opposition to Mylan Pharmaceuticals Inc.'s Motion to Dismiss for Improper Venue. (Silver, Daniel) |
| Oct 8, 2018 | 187 | Answer to Counterclaim (8) Docket Text: ANSWER to [146] Answer to Complaint, Counterclaim as to Defendants Glenmark Pharmaceuticals Inc., USA and Glenmark Pharmaceuticals Limited by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Oct 5, 2018 | 184 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendant Glenmark Pharmaceuticals, Inc., USA and Glenmark Pharmaceuticals Limiteds Objections and Responses to: 1) Plaintiffs First Set of Common Requests for the Production of Documents and Things (Nos. 1 30); and 2) Plaintiffs First Set of Common Interrogatories (Nos. 1- 7) filed by Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals Limited.(Poff, Adam) |
| Oct 5, 2018 | 185 | Answer to Complaint (30) Docket Text: ANSWER to [1] Complaint,,,,, by Emcure Pharmaceuticals, Heritage Pharmaceuticals Inc..(Phillips, John) |
| Oct 5, 2018 | 186 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Emcure Pharmaceuticals Ltd. for Heritage Pharmaceuticals Inc. filed by Emcure Pharmaceuticals, Heritage Pharmaceuticals Inc.. (Phillips, John) |
| Oct 4, 2018 | 170 | Stipulation of Dismissal (4) Docket Text: STIPULATION of Dismissal Against Defendant Par Pharmaceutical, Inc. by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Oct 4, 2018 | 171 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) Bionpharma's responses to Plaintiff's First Set of Common Interrogatories (Nos. 1-7); (2) Bionpharma's responses to Plaintiff's First Set of Common Requests for Production (Nos. 1-30); (3) Hetero's responses to Plaintiff's First Set of Common Interrogatories (Nos. 1-7); (4) Hetero's responses to Plaintiff's First Set of Common Requests for Production (Nos. 1-30); (5) Prinston's responses to Plaintiff's First Set of Common Interrogatories (Nos. 1-7); and (6) Prinston's responses to Plaintiff's First Set of Common Requests for Production (Nos. 1-30) filed by Bionpharma Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc..(Dorsney, Kenneth) |
| Oct 4, 2018 | 172 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Responses to First Set of Common Requests for Production and (2) Responses to First Set of Common Interrogatories filed by Alkem Laboratories Ltd..(Dorsney, Kenneth) |
| Oct 4, 2018 | 173 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Aurobindo's Responses to Plaintiff's First Set of Common Interrogatories (Nos. 1-7); and (2) Aurobindo's Responses to Plaintiff's First Set of Common Requests for Production (Nos. 1-30) filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
| Oct 4, 2018 | 174 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Defendants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Plaintiff's First Set of Common Interrogatories to All Defendants; and (2) Defendants Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Objections and Responses to Plaintiff's First Set of Common Requests for the Production of Documents and Things filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Oct 4, 2018 | 175 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Defendants Emcure Pharmaceuticals Ltd. and Heritage Pharmaceuticals Inc.'s Objections and Responses to Plaintiff's First Set of Common Interrogatories; and (2) Defendants Emcure Pharmaceuticals Ltd. and Heritage Pharmaceuticals Inc.'s Objections and Responses to Plaintiff's First Set of Common Requests for the Production of Documents and Things 1-30 filed by Emcure Pharmaceuticals, Heritage Pharmaceuticals Inc..(Haney, Megan) |
| Oct 4, 2018 | 176 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Defendant Accord Healthcare, Inc.'s (1) Responses and Objections to Plaintiff's First Set of Common Requests for the Production of Documents and Things [Nos. 1-30]; and (2) Responses and Objections to Plaintiff's First Set of Common Interrogatories [Nos. 1-7] filed by Accord Healthcare Inc..(Ormerod, Eve) |
| Oct 4, 2018 | 177 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Defendants Dr. Reddy's Laboratories, Ltd., Dr. Reddy's Laboratories, Inc.'s (1) Responses and Objections to Plaintiff's First Set of Common Requests for the Production of Documents and Things [Nos. 1-30]; and (2) Responses and Objections to Plaintiff's First Set of Common Interrogatories [Nos. 1-7] filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Ormerod, Eve) |
| Oct 4, 2018 | 178 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s (1) Responses and Objections to Plaintiff's First Set of Common Requests for the Production of Documents and Things [Nos. 1-30]; and (2) Responses and Objections to Plaintiff's First Set of Common Interrogatories [Nos. 1-7] filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Oct 4, 2018 | 179 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants Breckenridge Pharmaceutical, Inc. and Standard Chemical & Pharmaceutical Co., Ltd.'s: (1) Objections and Responses to Plaintiff's First Set of Common Requests for the Production of Documents and Things 1-30 and (2) Objections and Responses to Plaintiff's First Set of Common Interrogatories 1-7 filed by Breckenridge Pharmaceutical, Inc., Standard Chemical & Pharmaceutical Co., Ltd..(Farnan, Kelly) |
| Oct 4, 2018 | 180 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME for Mylan Pharmaceuticals to file reply brief in support of its Motion to Dismiss for Improper Venue to October 19, 2018 - filed by Mylan Pharmaceuticals, Inc.. (Rawnsley, Jason) |
| Oct 4, 2018 | 181 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Responses to Plaintiffs First Set of Common Interrogatories to All Defendants and Responses to Plaintiffs First Set of Common Requests for the Production of Documents and Things to All Defendants filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Oct 4, 2018 | 182 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Responses to Plaintiffs First Set of Common Interrogatories to All Defendants and Responses to Plaintiffs First Set of Common Requests for the Production of Documents and Things to All Defendants filed by Ezra Ventures, LLC.(Stamoulis, Stamatios) |
| Oct 4, 2018 | 183 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Defendant Mylan Pharmaceuticals Inc.'s Objections and Responses to Plaintiff's First Set of Common Requests for the Production of Documents and Things to All Defendants [Nos. 1-30]; and (2) Defendant Mylan Pharmaceuticals Inc.'s Objections and Responses to Plaintiff's First Set of Common Interrogatories to All Defendants [Nos. 1-7] filed by Mylan Pharmaceuticals, Inc..(Rawnsley, Jason) |
| Oct 3, 2018 | 167 | Answer to Counterclaim (8) Docket Text: ANSWER to [134] Answer to Complaint, Counterclaim as to Defendant HEC Pharm Co., Ltd and HEC Pharm USA Inc. by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Oct 3, 2018 | 168 | Redacted Document (26) Docket Text: REDACTED VERSION of [163] Answering Brief in Opposition, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Oct 3, 2018 | 169 | Redacted Document (7) Docket Text: REDACTED VERSION of [164] Declaration of Robert W. Trenchard in support of Answering Brief in Opposition to Motion to Dismiss for Improper Venue by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Oct 1, 2018 | 166 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Plaintiff's First Set of Requests for the Production of Documents and Things as to Defendants HEC Pharm Co., Ltd., HEC Pharm USA Inc., and Ezra Ventures LLC filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Sep 28, 2018 | 165 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) PLAINTIFFS VENUE-RELATED REQUESTS FOR THE PRODUCTION OF DOCUMENTS AND THINGS TO MYLAN PHARMACEUTICALS INC.; (2) PLAINTIFFS VENUE-RELATED INTERROGATORIES TO DEFENDANT MYLAN PHARMACEUTICALS INC.; (3) NOTICE OF DEPOSITION OF VENUE-RELATED 30(B)(6) DEPOSITION OF MYLAN PHARMACEUTICALS INC.; (4) SUBPOENAS TO MYLAN HOLDINGS INC. ; AND (5) SUBPOENAS TO MYLAN SECURITIZATION LLC filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Sep 24, 2018 | 162 | Letter (1) Docket Text: Letter to The Honorable Leonard P. Stark from John C. Phillips, Jr. regarding request to schedule a Rule 16 Conference. (Phillips, John) |
| Sep 19, 2018 | 160 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of 1) Defendants' Initial Disclosures; and 2) Glenmark's Initial Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery filed by Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals Limited.(Poff, Adam) |
| Sep 19, 2018 | 161 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Bionpharma, Hetero and Prinston's 26(a)(1) Initial Disclosures filed by Bionpharma Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc..(Dorsney, Kenneth) |
| Sep 17, 2018 | 139 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Bionpharma, Hetero and Prinston's Paragraph 3 Disclosures filed by Bionpharma Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc..(Dorsney, Kenneth) |
| Sep 17, 2018 | 140 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Initial Disclosures Pursuant to Paragrah 3 of the Delaware Default Standard for Discovery and (2) Initial Disclosures Purusant to F.R.C.P. 26(a) for Patent No. '405 filed by Alkem Laboratories Ltd..(Dorsney, Kenneth) |
| Sep 17, 2018 | 141 | Answer to Complaint (30) Docket Text: ANSWER to [1] Complaint,,,,, by Alkem Laboratories Ltd..(Dorsney, Kenneth) |
| Sep 17, 2018 | 142 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Alkem Laboratories Ltd.. (Dorsney, Kenneth) |
| Sep 17, 2018 | 143 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) Aurobindo's 26(a)(1) Initial Disclosures; and (2) Aurobindo's Paragraph 3 Disclosures filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
| Sep 17, 2018 | 144 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of (1) Defendants' First Joint Interrogatories to Plaintiff (Nos. 1-13); and (2) Defendants' First Joint Requests for Production to Plaintiff (Nos. 1-59) filed by Biocon Limited, Biocon Pharma, Inc., Cadila Healthcare Limited, Emcure Pharmaceuticals, Heritage Pharmaceuticals Inc., Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Sep 17, 2018 | 145 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Initial Disclosures of Defendants Biocon Limited and Biocon Pharma Inc.; and (2) Initial Disclosures of Defendants Biocon Limited and Biocon Pharma Inc. Pursuant to Paragraph 3 of the Default Standard for Discovery filed by Biocon Limited, Biocon Pharma, Inc..(Haney, Megan) |
| Sep 17, 2018 | 146 | Answer to Complaint (15) Docket Text: ANSWER to [1] Complaint,,,,, , COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals Limited.(Poff, Adam) |
| Sep 17, 2018 | 147 | Disclosure Statement (4) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Glenmark Pharmaceuticals Limited for Glenmark Pharmaceuticals Inc., USA filed by Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals Limited. (Poff, Adam) |
| Sep 17, 2018 | 148 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Defendants Accord Healthcare, Inc., Dr. Reddy's Laboratories, Ltd., Dr. Reddy's Laboratories, Inc., Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Delaware Paragraph 3 Disclosures and Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) filed by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Sep 17, 2018 | 149 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendant Par Pharmaceutical Inc.'s Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery filed by Par Pharmaceutical Inc..(Cragg, Tyler) |
| Sep 17, 2018 | 150 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Defendants Emcure Pharmaceuticals and Heritage Pharmaceuticals Inc.'s Disclosures Pursuant to Delaware Default Standard for Discovery Paragraph 3; and (2) Initial Disclosures of Defendants Emcure Pharmaceuticals and Heritage Pharmaceuticals Inc. Pursuant to Fed. Ri. Civ. P. 26(a)(1) filed by Emcure Pharmaceuticals, Heritage Pharmaceuticals Inc..(Haney, Megan) |
| Sep 17, 2018 | 151 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Defendant Par Pharmaceutical Inc.'s Rule 26(a)(1) Initial Disclosures filed by Par Pharmaceutical Inc..(Cragg, Tyler) |
| Sep 17, 2018 | 152 | Motion for Leave to Appear Pro Hac Vice (8) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney William R. Zimmerman, Benjamin A. Katzenellenbogen, Kimberly A. Kennedy and Forrest M. McClellan - filed by Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals Limited. (Poff, Adam) |
| Sep 17, 2018 | 153 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of (1) Zydus Pharmaceuticals (USA) and Cadila Healthcare Limited's Fed.R.Civ.P. 36(a)(1) Initial Disclosures; and (2) Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Limited's Initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Sep 17, 2018 | 154 | Notice of Service (13) Docket Text: NOTICE OF SERVICE of (1) PLAINTIFFS INITIAL DISCLOSURES PURSUANT TO FED. R. CIV. P. 26(a)(1) and (2) PLAINTIFFS RULE 3 DISCLOSURES filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Sep 17, 2018 | 155 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Rule 26(a)(1) Initial Disclosures and Paragraph 3 Disclosures filed by Breckenridge Pharmaceutical, Inc., Standard Chemical & Pharmaceutical Co., Ltd..(Farnan, Kelly) |
| Sep 17, 2018 | 156 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) and Discovery Disclosures Pursuant to the District of Delaware Default Standard for Discovery filed by Mylan Pharmaceuticals, Inc..(Rawnsley, Jason) |
| Sep 17, 2018 | 157 | Letter (3) Docket Text: Letter to The Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Requesting a Discovery Teleconference. (Silver, Daniel) |
| Sep 17, 2018 | 158 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Disclosures Pursuant to Federal Rule of Civil Procedure 26(A)(1) and Paragraph 3 of the Default Standard for Discovery filed by Ezra Ventures, LLC.(Stamoulis, Stamatios) |
| Sep 17, 2018 | 159 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Fed. R. Civ. P. 26(a)(1) Initial Disclosures and Disclosures Pursuant to Paragraph 3 of the Delaware Default Discovery Standard filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Sep 14, 2018 | 136 | Redacted Document (10) Docket Text: REDACTED VERSION of [119] Opening Brief in Support of Mylan Pharmaceuticals Inc.'s Motion to Dismiss for Improper Venue by Mylan Pharmaceuticals, Inc.. (Rawnsley, Jason) |
| Sep 14, 2018 | 137 | Main Document (4) Docket Text: REDACTED VERSION of [120] Declaration of Keith Meckstroth by Mylan Pharmaceuticals, Inc.. (Attachments: # (1) Exhibit 1)(Rawnsley, Jason) |
| Sep 14, 2018 | 137 | Exhibit 1 (1) |
| Sep 14, 2018 | 138 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME Plaintiff Novartis Pharmaceuticals Corporations deadline to respond to Mylan Pharmaceuticals Inc.s Motion to Dismiss for Improper Venue to September 28, 2018 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Sep 12, 2018 | 134 | Answer to Complaint (30) Docket Text: ANSWER to [1] Complaint,,,,, with Jury Demand , COUNTERCLAIM against All Plaintiffs by HEC Pharm USA Inc., HEC Pharm Group, HEC Pharm Co., Ltd..(Stamoulis, Stamatios) |
| Sep 12, 2018 | 135 | Disclosure Statement (3) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent HEC Pharm Group for HEC Pharm Co., Ltd., HEC Pharm USA Inc. filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc.. (Stamoulis, Stamatios) |
| Sep 11, 2018 | 130 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Aurobindo's Abbreviated New Drug Application filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc..(Dorsney, Kenneth) |
| Sep 11, 2018 | 131 | Order (1) Docket Text: ORDER re [117] MOTION for Leave to File Under Seal filed by Mylan Pharmaceuticals, Inc. Signed by Judge Leonard P. Stark on 9/10/18. (ntl) |
| Sep 11, 2018 | 132 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendants Glenmark Pharmaceuticals Inc., USA, and Glenmark Pharmaceuticals Limited's Abbreviated New Drug Application filed by Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals Limited.(Poff, Adam) |
| Sep 11, 2018 | 133 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Bicon's Abbreviated New Drug Application filed by Biocon Limited, Biocon Pharma, Inc..(Haney, Megan) |
| Sep 10, 2018 | 125 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendant Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application filed by Mylan Pharmaceuticals, Inc..(Rawnsley, Jason) |
| Sep 10, 2018 | 126 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Defendants Accord Healthcare, Inc., Dr. Reddy's Laboratories, Ltd., Dr. Reddy's Laboratories, Inc., Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Abbreviated New Drug Applications filed by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Sep 10, 2018 | 127 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Abbreviated New Drug Application filed by Emcure Pharmaceuticals, Heritage Pharmaceuticals Inc..(Haney, Megan) |
| Sep 10, 2018 | 128 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Abbreviated New Drug Application filed by Zydus Pharmaceuticals (USA) Inc..(Haney, Megan) |
| Sep 10, 2018 | 129 | Notice of Service (1) Docket Text: NOTICE OF SERVICE of Defendant Breckenridge Pharmaceutical, Inc.'s ANDA production, Bates stamped BPI-FINGO-000001 to BPI-FINGO-018645 filed by Breckenridge Pharmaceutical, Inc., Standard Chemical & Pharmaceutical Co., Ltd..(Farnan, Kelly) |
| Sep 7, 2018 | 116 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Alkem Laboratories, Ltd.'s ANDA production filed by Alkem Laboratories Ltd..(Dorsney, Kenneth) |
| Sep 7, 2018 | 117 | Main Document (2) Docket Text: MOTION for Leave to File Under Seal - filed by Mylan Pharmaceuticals, Inc.. (Attachments: # (1) Proposed Order)(Rawnsley, Jason) |
| Sep 7, 2018 | 117 | Proposed Order (1) |
| Sep 7, 2018 | 118 | Main Document (1) Docket Text: MOTION to Dismiss for Improper Venue - filed by Mylan Pharmaceuticals, Inc.. (Attachments: # (1) Text of Proposed Order)(Rawnsley, Jason) |
| Sep 7, 2018 | 118 | Text of Proposed Order (1) |
| Sep 7, 2018 | 121 | Notice of Service (2) Docket Text: NOTICE OF SERVICE of Defendant Par Pharmaceutical's Abbreviated New Drug Application filed by Par Pharmaceutical Inc..(Cragg, Tyler) |
| Sep 7, 2018 | 122 | Stipulation (4) Docket Text: STIPULATION to Remove Defendant HEC Pharm Group and Amend Caption to Reflect Same by HEC Pharm Co., Ltd., HEC Pharm Group, HEC Pharm USA Inc.. (Stamoulis, Stamatios) |
| Sep 7, 2018 | 123 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Abbreviated New Drug Application filed by HEC Pharm Co., Ltd., HEC Pharm USA Inc..(Stamoulis, Stamatios) |
| Sep 7, 2018 | 124 | Notice of Service (3) Docket Text: NOTICE OF SERVICE of Abbreviated New Drug Application filed by Ezra Ventures, LLC.(Stamoulis, Stamatios) |
| Sep 5, 2018 | 115 | Motion for Leave to Appear Pro Hac Vice (5) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Steven J. Udick - filed by HEC Pharm Co., Ltd., HEC Pharm Group, HEC Pharm USA Inc.. (Stamoulis, Stamatios) (Main Document 115 replaced on 9/7/2018) (ntl). |
| Sep 4, 2018 | 113 | Notice of Service (13) Docket Text: NOTICE OF SERVICE of (1) Plaintiff's First Set of Common Requests for the Production of Documents and Things to All Defendants; and (2) Plaintiff's First Set of Common Interrogatories to All Defendants filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Sep 4, 2018 | 114 | Answer to Counterclaim (8) Docket Text: ANSWER to [85] Answer to Complaint, Counterclaim as to Defendant Breckenridge Pharmaceutical, Inc. by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Aug 31, 2018 | 111 | Answer to Counterclaim (12) Docket Text: ANSWER to [80] Answer to Complaint,, Counterclaim, as to Defendants Nostrum Laboratories Inc., Nostrum Pharmaceuticals, LLC, MSN Laboratories Private Limited, and MSN Pharmaceuticals, Inc. by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Aug 31, 2018 | 112 | Notice of Service (13) Docket Text: NOTICE OF SERVICE of (1) Plaintiffs' Initial Disclosures of Accused Products and Asserted Patents; and (2) The File History for the Asserted Patent filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Aug 30, 2018 | 108 | Stipulation (6) Docket Text: STIPULATION and Proposed Order Staying the Case as to Strides by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Aug 30, 2018 | 109 | Answer to Counterclaim (9) Docket Text: ANSWER to [69] Answer to Complaint, Counterclaim as to Defendant Aurobindo Pharma Limited by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Aug 30, 2018 | 110 | Answer to Counterclaim (8) Docket Text: ANSWER to [69] Answer to Complaint, Counterclaim as to Defendant Hetero USA Inc., Hetero Labs Limited Unit-V, and Hetero Labs Limited by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Aug 29, 2018 | 104 | Answer to Counterclaim (7) Docket Text: ANSWER to [35] Answer to Complaint, Counterclaim as to Defendant Bionpharma Inc. by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Aug 29, 2018 | 105 | Answer to Counterclaim (8) Docket Text: ANSWER to [41] Answer to Complaint, Counterclaim as to Defendant Ezra Ventures LLC by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Aug 29, 2018 | 106 | Answer to Counterclaim (7) Docket Text: ANSWER to [33] Answer to Complaint, Counterclaim as to Defendant Prinston Pharmaceutical Inc. by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Aug 29, 2018 | 107 | Answer to Counterclaim (9) Docket Text: ANSWER to [62] Answer to Complaint, Counterclaim as to Defendants Biocon Limited and Biocon Pharma, Inc. by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Aug 27, 2018 | 103 | Main Document (19) Docket Text: PROPOSED ORDER Proposed Scheduling Order by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Letter to the Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding Proposed Scheduling Order)(Silver, Daniel) |
| Aug 27, 2018 | 103 | Letter to the Honorable Leonard P. Stark from Daniel M. Silver, Esq. regarding (2) |
| Aug 23, 2018 | 102 | Motion for Leave to Appear Pro Hac Vice (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Louis H. Weinstein - filed by Accord Healthcare Inc., Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Ormerod, Eve) |
| Aug 22, 2018 | 99 | Motion for Leave to Appear Pro Hac Vice (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Elaine Herrmann Blais and Cindy Chang - filed by Emcure Pharmaceuticals, Heritage Pharmaceuticals Inc.. (Haney, Megan) |
| Aug 22, 2018 | 100 | Motion for Leave to Appear Pro Hac Vice (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Michael Cottler - filed by Emcure Pharmaceuticals, Heritage Pharmaceuticals Inc.. (Haney, Megan) |
| Aug 22, 2018 | 101 | Stipulation of Dismissal (4) Docket Text: STIPULATION of Dismissal Against Defendant First Time US Generics LLC by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Aug 21, 2018 | 98 | Motion for Leave to Appear Pro Hac Vice (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney George J. Barry III and Attorney Timothy H. Kratz - filed by Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc.. (Dorsney, Kenneth) |
| Aug 17, 2018 | 95 | Notice of Appearance (1) Docket Text: NOTICE of Appearance by John C. Phillips, Jr on behalf of Emcure Pharmaceuticals, Heritage Pharmaceuticals Inc. (Phillips, John) |
| Aug 17, 2018 | 96 | Notice of Appearance (1) Docket Text: NOTICE of Appearance by Megan C. Haney on behalf of Emcure Pharmaceuticals, Heritage Pharmaceuticals Inc. (Haney, Megan) |
| Aug 17, 2018 | 97 | Motion for Leave to Appear Pro Hac Vice (7) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Mieke Malmerg, Paul Skiermont, and Sarah Spires - filed by HEC Pharm Co., Ltd., HEC Pharm Group, HEC Pharm USA Inc.. (Stamoulis, Stamatios) |
| Aug 15, 2018 | 92 | Motion for Leave to Appear Pro Hac Vice (5) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Michael J. Gaertner, David B. Abramowitz, Carolyn A. Blessing and Emily L. Savas - filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan) |
| Aug 15, 2018 | 93 | Motion for Leave to Appear Pro Hac Vice (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Jonathan B. Turpin - filed by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc.. (Haney, Megan) |
| Aug 15, 2018 | 94 | Motion for Leave to Appear Pro Hac Vice (4) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Shannon M. Bloodworth and Brandon M. White - filed by Mylan Pharmaceuticals, Inc.. (Cottrell, Frederick) |
| Aug 14, 2018 | 89 | Stipulation (4) Docket Text: Joint STIPULATION and [Proposed] Order Dismissing Without Prejudice Defendant Intas Pharmaceuticals Ltd. and Amending Caption to Reflect Same by Accord Healthcare Inc., Intas Pharmaceuticals Limited. (Belgam, Neal) |
| Aug 14, 2018 | 90 | Motion for Leave to Appear Pro Hac Vice (5) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Stephen R. Auten, Attorney Richard T. Ruzich, Attorney Jaimin H. Shah and Attorney Roshan P. Shrestha - filed by Alkem Laboratories Ltd.. (Dorsney, Kenneth) |
| Aug 14, 2018 | 91 | Stipulation (4) Docket Text: Joint STIPULATION Extend Time To Respond to the Complaint to September 12, 2018 for Defendants HEC Pharm Co., Ltd., HEC Pharm Group and HEC Pharm USA Inc. by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Aug 13, 2018 | 85 | Answer to Complaint (30) Docket Text: ANSWER to [1] Complaint,,,,, Affirmative Defenses, COUNTERCLAIM against All Plaintiffs by Breckenridge Pharmaceutical, Inc., Standard Chemical & Pharmaceutical Co., Ltd..(Farnan, Kelly) |
| Aug 13, 2018 | 86 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Standard Chemical & Pharmaceutical Co., Ltd.. (Farnan, Kelly) |
| Aug 13, 2018 | 87 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Pensa Pharma S.A. for Breckenridge Pharmaceutical, Inc. filed by Breckenridge Pharmaceutical, Inc.. (Farnan, Kelly) |
| Aug 13, 2018 | 88 | Motion for Leave to Appear Pro Hac Vice (5) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Aaron F. Barkoff and Alejandro Menchaca - filed by Ezra Ventures, LLC. (Stamoulis, Stamatios) |
| Aug 10, 2018 | N/A | SO ORDERED (0) |
| Aug 10, 2018 | N/A | SO ORDERED (0) |
| Aug 10, 2018 | 78 | Notice of Appearance (1) Docket Text: NOTICE of Appearance by Megan C. Haney on behalf of Biocon Limited, Biocon Pharma, Inc. (Haney, Megan) |
| Aug 10, 2018 | 79 | Notice of Appearance (1) Docket Text: NOTICE of Appearance by Megan C. Haney on behalf of Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc. (Haney, Megan) |
| Aug 10, 2018 | 80 | Answer to Complaint (30) Docket Text: ANSWER to [1] Complaint,,,,, for Declaratory Judgment, COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Nostrum Pharmaceuticals, LLC, MSN Laboratories Private Limited, Nostrum Laboratories Inc., MSN Pharmaceuticals Inc..(Finger, David) |
| Aug 10, 2018 | 81 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent MSN Laboratories Private Limited for MSN Laboratories Private Limited, MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., MSN Pharmaceuticals Inc. filed by MSN Laboratories Private Limited, MSN Pharmaceuticals Inc.. (Finger, David) |
| Aug 10, 2018 | 82 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Nostrum Laboratories Inc., Nostrum Pharmaceuticals, LLC. (Finger, David) |
| Aug 10, 2018 | 83 | Declaration (2) |
| Aug 10, 2018 | 83 | Exhibit A-B (6) |
| Aug 10, 2018 | 83 | Main Document (2) Docket Text: DECLARATION of Mailing regarding service on Emcure Pharmaceuticals made on July 19, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-B)(Silver, Daniel) |
| Aug 9, 2018 | 66 | Answer to Complaint (12) Docket Text: ANSWER to [1] Complaint,,,,, , COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Hetero USA Inc., Hetero Labs Limited Unit-V, Hetero Labs Limited.(Dorsney, Kenneth) |
| Aug 9, 2018 | 67 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Hetero Drugs Limited, Corporate Parent Hetero Labs Limited for Hetero USA Inc. filed by Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc.. (Dorsney, Kenneth) |
| Aug 9, 2018 | 68 | Motion for Leave to Appear Pro Hac Vice (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Howard S. Suh - filed by Bionpharma Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Prinston Pharmaceutical Inc.. (Dorsney, Kenneth) |
| Aug 9, 2018 | 69 | Answer to Complaint (30) Docket Text: ANSWER to [1] Complaint,,,,, , COUNTERCLAIM against All Plaintiffs by Aurobindo Pharma USA, Inc., Aurobindo Pharma Limited.(Dorsney, Kenneth) |
| Aug 9, 2018 | 70 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Aurobindo Pharma Limited for Aurobindo Pharma USA, Inc. filed by Aurobindo Pharma USA, Inc.. (Dorsney, Kenneth) |
| Aug 9, 2018 | 71 | Answer to Complaint (30) Docket Text: ANSWER to [1] Complaint,,,,, and Affirmative Defenses by Cadila Healthcare Limited, Zydus Pharmaceuticals (USA) Inc..(Phillips, John) |
| Aug 9, 2018 | 72 | Stipulation (4) Docket Text: STIPULATION and [Proposed] Order by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Aug 9, 2018 | 73 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Cadila Healthcare Limited for Zydus Pharmaceuticals (USA) Inc. filed by Zydus Pharmaceuticals (USA) Inc.. (Phillips, John) |
| Aug 9, 2018 | 74 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent No parent company for Cadila Healthcare Limited filed by Cadila Healthcare Limited. (Phillips, John) |
| Aug 9, 2018 | 75 | Answer to Complaint (8) Docket Text: ANSWER to [1] Complaint,,,,, and Defenses by Par Pharmaceutical Inc..(Cragg, Tyler) |
| Aug 9, 2018 | 76 | Motion for Leave to Appear Pro Hac Vice (5) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney David H. Silverstein, Aziz Burgy, and Ricardo S. Camposanto - filed by Par Pharmaceutical Inc.. (Cragg, Tyler) |
| Aug 9, 2018 | 77 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Endo International PLC for Par Pharmaceutical Inc. filed by Par Pharmaceutical Inc.. (Cragg, Tyler) |
| Aug 8, 2018 | N/A | SO ORDERED (0) |
| Aug 8, 2018 | N/A | SO ORDERED (0) |
| Aug 8, 2018 | N/A | SO ORDERED (0) |
| Aug 8, 2018 | N/A | SO ORDERED (0) |
| Aug 8, 2018 | 30 | Stipulation (4) Docket Text: STIPULATION and [Proposed] Order by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Aug 8, 2018 | 31 | Stipulation to EXTEND Time (4) Docket Text: STIPULATION TO EXTEND TIME to respond to the Complaint to September 7, 2018 - filed by Mylan Pharmaceuticals, Inc.. (Rawnsley, Jason) |
| Aug 8, 2018 | 32 | Notice of Appearance (1) Docket Text: NOTICE of Appearance by Frederick L. Cottrell, III on behalf of Mylan Pharmaceuticals, Inc. (Cottrell, Frederick) |
| Aug 8, 2018 | 33 | Answer to Complaint (11) Docket Text: ANSWER to [1] Complaint,,,,, for Patent Infringement, COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Prinston Pharmaceutical Inc..(Dorsney, Kenneth) |
| Aug 8, 2018 | 34 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Zhejiang Huahai Pharmaceutical Co., Ltd. for Prinston Pharmaceutical Inc. filed by Prinston Pharmaceutical Inc.. (Dorsney, Kenneth) |
| Aug 8, 2018 | 35 | Answer to Complaint (11) Docket Text: ANSWER to [1] Complaint,,,,, , COUNTERCLAIM against All Plaintiffs by Bionpharma Inc..(Dorsney, Kenneth) |
| Aug 8, 2018 | 36 | Declaration (2) |
| Aug 8, 2018 | 36 | Exhibit A-B (6) |
| Aug 8, 2018 | 37 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Bionpharma Inc.. (Dorsney, Kenneth) |
| Aug 8, 2018 | 38 | Declaration (2) |
| Aug 8, 2018 | 38 | Exhibit A-B (6) |
| Aug 8, 2018 | 39 | Declaration (2) |
| Aug 8, 2018 | 39 | Exhibit A-B (6) |
| Aug 8, 2018 | 40 | Declaration (2) |
| Aug 8, 2018 | 40 | Exhibit A-B (6) |
| Aug 8, 2018 | 41 | Answer to Complaint (30) Docket Text: ANSWER to [1] Complaint,,,,, , COUNTERCLAIM against All Plaintiffs by Ezra Ventures, LLC.(Stamoulis, Stamatios) |
| Aug 8, 2018 | 42 | Declaration (2) |
| Aug 8, 2018 | 42 | Exhibit A-B (6) |
| Aug 8, 2018 | 43 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Ezra Innovations LLC for Ezra Ventures, LLC filed by Ezra Ventures, LLC. (Stamoulis, Stamatios) |
| Aug 8, 2018 | 44 | Declaration (2) |
| Aug 8, 2018 | 44 | Exhibit A-B (6) |
| Aug 8, 2018 | 45 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME re Answer to Complaint to through and including August 13, 2018 - filed by Breckenridge Pharmaceutical, Inc., Standard Chemical & Pharmaceutical Co., Ltd.. (Farnan, Kelly) |
| Aug 8, 2018 | 46 | Answer to Complaint (14) Docket Text: ANSWER to [1] Complaint,,,,, and Additional Defenses by Accord Healthcare Inc..(Ormerod, Eve) |
| Aug 8, 2018 | 47 | Answer to Complaint (13) Docket Text: ANSWER to [1] Complaint,,,,, and Additional Defenses by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd..(Ormerod, Eve) |
| Aug 8, 2018 | 48 | Answer to Complaint (14) Docket Text: ANSWER to [1] Complaint,,,,, and Additional Defenses by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) |
| Aug 8, 2018 | 49 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Intas Pharmaceuticals Limited for Accord Healthcare Inc. filed by Accord Healthcare Inc.. (Belgam, Neal) |
| Aug 8, 2018 | 50 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Dr. Reddys Laboratories, Ltd. for Dr. Reddys Laboratories, Inc. filed by Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd.. (Belgam, Neal) |
| Aug 8, 2018 | 51 | Declaration (2) |
| Aug 8, 2018 | 51 | Exhibit A-B (6) |
| Aug 8, 2018 | 52 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Torrent Private Ltd. for Torrent Pharmaceuticals Ltd.; Corporate Parent Torrent Pharmaceuticals Ltd. for Torrent Pharma Inc. filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Belgam, Neal) |
| Aug 8, 2018 | 53 | Declaration (2) |
| Aug 8, 2018 | 53 | Exhibit A-B (6) |
| Aug 8, 2018 | 54 | Declaration (2) |
| Aug 8, 2018 | 54 | Exhibit A-B (6) |
| Aug 8, 2018 | 55 | Declaration (2) |
| Aug 8, 2018 | 55 | Exhibit A-B (6) |
| Aug 8, 2018 | 56 | Declaration (2) |
| Aug 8, 2018 | 56 | Exhibit A-B (6) |
| Aug 8, 2018 | 57 | Declaration (2) |
| Aug 8, 2018 | 57 | Exhibit A-B (6) |
| Aug 8, 2018 | 58 | Declaration (2) |
| Aug 8, 2018 | 58 | Exhibit A-B (6) |
| Aug 8, 2018 | 59 | Declaration (2) |
| Aug 8, 2018 | 59 | Exhibit A-B (6) |
| Aug 8, 2018 | 60 | Declaration (2) |
| Aug 8, 2018 | 60 | Exhibit A-B (6) |
| Aug 8, 2018 | 61 | Declaration (2) |
| Aug 8, 2018 | 61 | Exhibit A-B (6) |
| Aug 8, 2018 | 62 | Answer to Complaint (30) Docket Text: ANSWER to [1] Complaint,,,,, Affirmative Defenses and, COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Biocon Limited, Biocon Pharma, Inc..(Phillips, John) |
| Aug 8, 2018 | 63 | Declaration (2) |
| Aug 8, 2018 | 63 | Exhibit A-B (6) |
| Aug 8, 2018 | 64 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent No parent company for Biocon Limited; Corporate Parent Biocon Limited for Biocon Pharma, Inc. filed by Biocon Limited, Biocon Pharma, Inc.. (Phillips, John) |
| Aug 8, 2018 | 65 | Declaration (2) |
| Aug 8, 2018 | 65 | Exhibit A-B (6) |
| Aug 8, 2018 | 36 | Main Document (2) Docket Text: DECLARATION of Mailing regarding service on Accord Healthcare Inc. made on July 19, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-B)(Silver, Daniel) |
| Aug 8, 2018 | 38 | Main Document (2) Docket Text: DECLARATION of Mailing regarding service on Alkem Laboratories, Ltd. made on July 19, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-B)(Silver, Daniel) |
| Aug 8, 2018 | 39 | Main Document (2) Docket Text: DECLARATION of Mailing regarding service on Aurobindo Pharma Limited made on July 19, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-B)(Silver, Daniel) |
| Aug 8, 2018 | 40 | Main Document (2) Docket Text: DECLARATION of Mailing regarding service on Biocon Limited made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-B)(Silver, Daniel) |
| Aug 8, 2018 | 42 | Main Document (2) Docket Text: DECLARATION of Mailing regarding service on Breckenridge Pharmaceutical, Inc. made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-B)(Silver, Daniel) |
| Aug 8, 2018 | 44 | Main Document (2) Docket Text: DECLARATION of Mailing regarding service on Standard Chemical & Pharmaceutical Co., Ltd. made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-B)(Silver, Daniel) |
| Aug 8, 2018 | 51 | Main Document (2) Docket Text: DECLARATION of Mailing regarding service on Dr, Reddy's Laboratories, Inc. made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-B)(Silver, Daniel) |
| Aug 8, 2018 | 53 | Main Document (2) Docket Text: DECLARATION of Mailing regarding service on Dr. Reddy's Laboratories, Ltd. made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-B)(Silver, Daniel) |
| Aug 8, 2018 | 54 | Main Document (2) Docket Text: DECLARATION of Mailing regarding service on Ezra Ventures, LLC made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-B)(Silver, Daniel) |
| Aug 8, 2018 | 55 | Main Document (2) Docket Text: DECLARATION of Mailing regarding service on Glenmark Pharmaceuticals Inc., USA made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-B)(Silver, Daniel) |
| Aug 8, 2018 | 56 | Main Document (2) Docket Text: DECLARATION of Mailing regarding service on Glenmark Pharmaceuticals Limited made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-B)(Silver, Daniel) |
| Aug 8, 2018 | 57 | Main Document (2) Docket Text: DECLARATION of Mailing regarding service on HEC Pharm Co., Ltd. made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-B)(Silver, Daniel) |
| Aug 8, 2018 | 58 | Main Document (2) Docket Text: DECLARATION of Mailing regarding service on HEC Pharm Group made on July 19, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-B)(Silver, Daniel) |
| Aug 8, 2018 | 59 | Main Document (2) Docket Text: DECLARATION of Mailing regarding service on HEC Pharm USA Inc. made on July 23, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-B)(Silver, Daniel) |
| Aug 8, 2018 | 60 | Main Document (2) Docket Text: DECLARATION of Mailing regarding service on Hetero Labs Limited Unit-V made on July 19, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-B)(Silver, Daniel) |
| Aug 8, 2018 | 61 | Main Document (2) Docket Text: DECLARATION of Mailing regarding service on Hetero Labs Limited made on July 19, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-B)(Silver, Daniel) |
| Aug 8, 2018 | 63 | Main Document (2) Docket Text: DECLARATION of Mailing regarding service on Nostrum Laboratories Inc., USA made on July 19, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-B)(Silver, Daniel) |
| Aug 8, 2018 | 65 | Main Document (2) Docket Text: DECLARATION of Mailing regarding service on MSN Laboratories Private Limited made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-B)(Silver, Daniel) |
| Aug 7, 2018 | N/A | Add Attorneys Pro Hac Vice (0) |
| Aug 6, 2018 | 26 | Stipulation of Dismissal (5) Docket Text: STIPULATION of Dismissal of S&B Pharma, Inc. without prejudice and Amending Caption by Alkem Laboratories Ltd.. (Dorsney, Kenneth) |
| Aug 6, 2018 | 28 | Notice of Appearance (1) Docket Text: NOTICE of Appearance by Helena C. Rychlicki on behalf of Strides Global Pharma Private Limited, Strides Pharma, Inc. (Rychlicki, Helena) |
| Aug 6, 2018 | 29 | Stipulation to EXTEND Time (4) Docket Text: STIPULATION TO EXTEND TIME to ANSWER complaint to September 7, 2018 - filed by Strides Global Pharma Private Limited, Strides Pharma, Inc.. (Rychlicki, Helena) |
| Aug 3, 2018 | 19 | Stipulation (3) Docket Text: STIPULATION and [Proposed] Order as to Defendant First Time US Generics LLC by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| Aug 3, 2018 | 20 | Declaration (2) |
| Aug 3, 2018 | 20 | Exhibit A-B (6) |
| Aug 3, 2018 | 21 | Declaration (2) |
| Aug 3, 2018 | 21 | Exhibit A-B (6) |
| Aug 3, 2018 | 22 | Declaration (2) |
| Aug 3, 2018 | 22 | Exhibit A-B (6) |
| Aug 3, 2018 | 23 | Declaration (2) |
| Aug 3, 2018 | 23 | Exhibit A-B (6) |
| Aug 3, 2018 | 24 | Declaration (2) |
| Aug 3, 2018 | 24 | Exhibit A-B (6) |
| Aug 3, 2018 | 25 | Stipulation to EXTEND Time (5) Docket Text: STIPULATION TO EXTEND TIME Respond to Complaint to September 17, 2018 - filed by Alkem Laboratories Ltd.. (Dorsney, Kenneth) |
| Aug 3, 2018 | 20 | Main Document (2) Docket Text: DECLARATION of Mailing Regarding Service on Defendant Zydus Pharmaceuticals (USA) Inc. made on July 19, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-B)(Silver, Daniel) |
| Aug 3, 2018 | 21 | Main Document (2) Docket Text: DECLARATION of Mailing regarding service on Strides Global Pharma Private Limited made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-B)(Silver, Daniel) |
| Aug 3, 2018 | 22 | Main Document (2) Docket Text: DECLARATION of Mailing regarding service on Strides Pharma, Inc. made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-B)(Silver, Daniel) |
| Aug 3, 2018 | 23 | Main Document (2) Docket Text: DECLARATION of Mailing regarding Service on Torrent Pharma Inc. made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-B)(Silver, Daniel) |
| Aug 3, 2018 | 24 | Main Document (2) Docket Text: DECLARATION of Mailing regarding Service on Torrent Pharmaceuticals Ltd. made on July 18, 2018 by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-B)(Silver, Daniel) |
| Jul 27, 2018 | N/A | Add Attorneys Pro Hac Vice (0) |
| Jul 27, 2018 | N/A | Add Attorneys Pro Hac Vice (0) |
| Jul 24, 2018 | N/A | SO ORDERED (0) |
| Jul 24, 2018 | 7 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. Biocon Pharma, Inc. served on 7/19/2018, answer due 8/9/2018. (Silver, Daniel) |
| Jul 24, 2018 | 8 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. First Time US Generics LLC served on 7/18/2018, answer due 8/8/2018. (Silver, Daniel) |
| Jul 24, 2018 | 9 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. Aurobindo Pharma USA, Inc. served on 7/19/2018, answer due 8/9/2018. (Silver, Daniel) |
| Jul 24, 2018 | 10 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. Heritage Pharmaceuticals Inc. served on 7/19/2018, answer due 8/9/2018. (Silver, Daniel) |
| Jul 24, 2018 | 11 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. Par Pharmaceutical Inc. served on 7/19/2018, answer due 8/9/2018. (Silver, Daniel) |
| Jul 24, 2018 | 12 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. Hetero USA Inc. served on 7/19/2018, answer due 8/9/2018. (Silver, Daniel) |
| Jul 24, 2018 | 13 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. MSN Pharmaceuticals Inc. served on 7/18/2018, answer due 8/8/2018. (Silver, Daniel) |
| Jul 24, 2018 | 14 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. S&B Pharma, Inc. served on 7/18/2018, answer due 8/8/2018. (Silver, Daniel) |
| Jul 24, 2018 | 15 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. Prinston Pharmaceutical Inc. served on 7/18/2018, answer due 8/8/2018. (Silver, Daniel) |
| Jul 24, 2018 | 16 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. Mylan Pharmaceuticals, Inc. served on 7/18/2018, answer due 8/8/2018. (Silver, Daniel) |
| Jul 24, 2018 | 17 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. Nostrum Pharmaceuticals, LLC served on 7/18/2018, answer due 8/8/2018. (Silver, Daniel) |
| Jul 24, 2018 | 18 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by Novartis Pharmaceuticals Corporation. Bionpharma Inc. served on 7/18/2018, answer due 8/8/2018. (Silver, Daniel) |
| Jul 23, 2018 | N/A | Summons Reissued (0) Docket Text: Summons Reissued with Magistrate Consent Notice attached as to HEC Pharm USA Inc. (jcs) |
| Jul 23, 2018 | 6 | Certifications for Jane M. Love, Robert Trenchard, Paul E. Torchia, and Andrew (4) |
| Jul 23, 2018 | 6 | Main Document (3) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Jane M. Love, Robert Trenchard, Paul E. Torchia, and Andrew P. Blythe - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Certifications for Jane M. Love, Robert Trenchard, Paul E. Torchia, and Andrew P. Blythe)(Silver, Daniel) |
| Jul 19, 2018 | N/A | Summons Reissued (0) |
| Jul 19, 2018 | N/A | Summons Reissued (0) |
| Jul 18, 2018 | N/A | Summons Issued (0) Docket Text: Summons Issued with Magistrate Consent Notice attached as to Accord Healthcare Inc. on 7/18/2018; Alkem Laboratories Ltd. on 7/18/2018; Aurobindo Pharma Limited on 7/18/2018; Aurobindo Pharma USA, Inc. on 7/18/2018; Biocon Limited on 7/18/2018; Biocon Pharma, Inc. on 7/18/2018; Bionpharma Inc. on 7/18/2018; Breckenridge Pharmaceutical, Inc. on 7/18/2018; Cadila Healthcare Limited on 7/18/2018; Dr. Reddys Laboratories, Inc. on 7/18/2018; Dr. Reddys Laboratories, Ltd. on 7/18/2018; Emcure Pharmaceuticals on 7/18/2018; Ezra Ventures, LLC on 7/18/2018; First Time US Generics LLC on 7/18/2018; Glenmark Pharmaceuticals Inc., USA on 7/18/2018; Glenmark Pharmaceuticals Limited on 7/18/2018; HEC Pharm Co., Ltd. on 7/18/2018; HEC Pharm Group on 7/18/2018; HEC Pharm USA Inc. on 7/18/2018; Heritage Pharmaceuticals Inc. on 7/18/2018; Hetero Labs Limited on 7/18/2018; Hetero Labs Limited Unit-V on 7/18/2018; Hetero USA Inc. on 7/18/2018; Intas Pharmaceuticals Limited on 7/18/2018; MSN Laboratories Private Limited on 7/18/2018; MSN Pharmaceuticals Inc. on 7/18/2018; Mylan Pharmaceuticals, Inc. on 7/18/2018; Nostrum Laboratories Inc. on 7/18/2018; Nostrum Pharmaceuticals, LLC on 7/18/2018; Par Pharmaceutical Inc. on 7/18/2018; Prinston Pharmaceutical Inc. on 7/18/2018; S&B Pharma, Inc. on 7/18/2018; Standard Chemical & Pharmaceutical Co., Ltd. on 7/18/2018; Strides Global Pharma Private Limited on 7/18/2018; Strides Pharma, Inc. on 7/18/2018; Torrent Pharma Inc. on 7/18/2018; Torrent Pharmaceuticals Ltd. on 7/18/2018; Zydus Pharmaceuticals (USA) Inc. on 7/18/2018. (sar) |
| Jul 16, 2018 | N/A | No Summons Issued (0) Docket Text: No Summons Issued. (nmg) |
| Jul 16, 2018 | 1 | Complaint (55) |
| Jul 16, 2018 | 1 | Exhibit A-B (71) |
| Jul 16, 2018 | 1 | Civil Cover Sheet (2) |
| Jul 16, 2018 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (nmg) |
| Jul 16, 2018 | 3 | ANDA Form (4) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: See Attached. Date of Expiration of Patent: 6/25/2027. (nmg) |
| Jul 16, 2018 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,187,405. (nmg) |
| Jul 16, 2018 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (nmg) |
| Jul 16, 2018 | 1 | Main Document (55) Docket Text: COMPLAINT for PATENT INFRINGEMENT filed against Accord Healthcare Inc., Alkem Laboratories Ltd., Aurobindo Pharma Limited, Aurobindo Pharma USA, Inc., Biocon Limited, Biocon Pharma, Inc., Bionpharma Inc., Breckenridge Pharmaceutical, Inc., Cadila Healthcare Limited, Dr. Reddys Laboratories, Inc., Dr. Reddys Laboratories, Ltd., Emcure Pharmaceuticals, Ezra Ventures, LLC, First Time US Generics LLC, Glenmark Pharmaceuticals Inc., USA, Glenmark Pharmaceuticals Limited, HEC Pharm Co., Ltd., HEC Pharm Group, HEC Pharm USA Inc., Heritage Pharmaceuticals Inc., Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero USA Inc., Intas Pharmaceuticals Limited, MSN Laboratories Private Limited, MSN Pharmaceuticals Inc., Mylan Pharmaceuticals, Inc., Nostrum Laboratories Inc., Nostrum Pharmaceuticals, LLC, Par Pharmaceutical Inc., Prinston Pharmaceutical Inc., S&B Pharma, Inc., Standard Chemical & Pharmaceutical Co., Ltd., Strides Global Pharma Private Limited, Strides Pharma, Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Zydus Pharmaceuticals (USA) Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2420075.) - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A-B, # (2) Civil Cover Sheet)(nmg) |
| Jul 16, 2018 | 1 | Complaint* (1) |
